{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00023114", "CSN": null, "TRF": "ORD_1450681_01", "MRN": "48800722", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1191858", "clinicalId": "1193228", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1450681_01", "SampleName": "US1390521.01", "Version": "0", "Sample": {"FM_Id": "ORD_1450681_01", "SampleId": "US1390521.01", "BlockId": "S111-30912A", "TRFNumber": "ORD_1450681_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_09_07", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-97892", "MRN": "48800722", "FullName": "\u8d99\u975c", "FirstName": "Ching", "LastName": "Chao", "SubmittedDiagnosis": "Metastatic adenocarcinoma, Cerebrum", "Gender": "Female", "DOB": "1985_03_04", "OrderingMD": "\u8cf4\u5cfb\u6bc5", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2022_08_11", "ReceivedDate": "2022-09-27 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Adenocarcinoma, NOS"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "19", "clinicalTrialCount": "14", "resistiveCount": "0", "sensitizingCount": "9"}, "VariantProperties": {"VariantProperty": [{"geneName": "ATM", "isVUS": "true", "variantName": "H42R"}, {"geneName": "BAP1", "isVUS": "true", "variantName": "A321T"}, {"geneName": "CDK12", "isVUS": "true", "variantName": "amplification"}, {"geneName": "ERBB4", "isVUS": "true", "variantName": "M322K"}, {"geneName": "FANCC", "isVUS": "true", "variantName": "I80T"}, {"geneName": "LYN", "isVUS": "true", "variantName": "rearrangement"}, {"geneName": "RNF43", "isVUS": "true", "variantName": "R145Q"}, {"geneName": "STAG2", "isVUS": "true", "variantName": "R760C"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CTNNB1", "Include": "true", "Alterations": {"Alteration": {"Name": "S45P", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "S45P"}}, "Interpretation": "CTNNB1 encodes beta_catenin, a key downstream component of the WNT signaling pathway. Beta_catenin interacts with cadherin to regulate cell_cell adhesion; as a component of the WNT pathway, it also plays a role in development, cell proliferation, and cell differentiation (Kikuchi, 2000; 10679188). CTNNB1 exon 3 mutations, such as observed here, lead to increased beta_catenin protein stability and activation of the WNT pathway, and are considered to be activating (Anastas and Moon, 2013; 23258168, Fukuchi et al., 1998; 9721853, Kikuchi et al., 2003; 12824913, Takahashi et al., 2006; 16523258, Tanaka et al., 2001; 11731417, Abraham et al., 2002; 11943721, Austinat et al., 2008; 18282277, Wu et al., 2003; 12820959, Provost et al., 2005; 15829978, Polakis, 1999; 10072352, Segditsas and Tomlinson, 2006; 17143297, Barth et al., 1997; 9024698, Harada et al., 1999; 10545105, Hsu et al., 1998; 9671490, Breuhahn et al., 2008; 18491352, Soon et al., 2008; 18515740, Tacon et al., 2011; 21212436, Simon and Hammer, 2012; 22266195, Hirotsu et al., 2016; 26850916). CTNNB1 mutations are common in various solid tumors and are often seen in endometrial (14%), hepatobiliary (11%), melanoma (4.7%), prostate (3.4%), and non_small cell lung (2.9%) cancer (NSCLC) (cBio_Zehir et al., 2017; 28481359). Aberrant beta_catenin expression has been associated with poor prognosis in lung adenocarcinoma and other non_small cell lung carcinomas (Nozawa et al., 2006; 16843618, Chiu et al., 2012; 22402266, Kim et al., 2013; 23483484). Low membrane expression of beta_catenin has been associated with poor prognosis in ovarian endometrioid and endometrial carcinomas (Rosen et al., 2010; 19820688, Athanassiadou et al., 2007; 17504383). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). Mutation or activation of CTNNB1 signaling has been shown to increase mTOR signaling, promote tumorigenesis, and respond to mTOR inhibition in preclinical studies (Tanwar et al., 2009; 19403928, Tanwar et al., 2011; 21695255, Fujishita et al., 2008; 18768809). Small studies have reported clinical benefit following treatment of everolimus combined with other targeted agents for patients with CTNNB1_mutated hepatocellular carcinoma (Bhoori et al., 2010; 20347502, Janku et al., 2014; 24931142) or endometrial carcinoma (Slomovitz et al., 2015; 25624430). In preclinical studies, CTNNB1 activating mutations have been shown to increase expression of WNT pathway member DKK1, which may promote tumor cell proliferation and immune evasion (Niida et al., 2004; 15378020, Chamorro et al., 2005; 15592430, Kagey and He, 2017; 28574171). A Phase 1 trial of DKK1_targeting antibody DKN_01 in combination with paclitaxel in esophageal cancer reported a PR rate in 2 out of 4 patients and SD rate of in 1 out of 4 patients with CTNNB1 activating mutations, compared with 24% (10/41) PR and 37% (15/41) SD in unselected patients (Kagey et al., 2017; AACR Abstract 369). Multiple preclinical studies in cancer models harboring CTNNB1 mutation or beta_catenin pathway activation have reported activation of the NOTCH pathway and sensitivity to pharmacologic inhibition of NOTCH signaling by gamma_secretase inhibitors (Kwon et al., 2011; 21841793, Arcaroli et al., 2013; 23868008, Shang et al., 2015; 26349011, Kode et al., 2014; 24429522). Phase 1 and 2 clinical trials of gamma_secretase inhibitor PF_03084014 have shown high response rates in patients with desmoid tumors, which are driven by activating CTNNB1 mutations in the majority of cases (Kummar et al., 2015; ASCO Abstract 10563)(Messersmith et al., 2015; 25231399), suggesting CTNNB1_mutated tumors may be sensitive to gamma_secretase inhibitors. Although WNT pathway inhibitors have been explored preclinically in CTNNB1_mutated cells, clinical data supporting this therapeutic approach are lacking (Zhu et al., 2012; 22964660, Tanwar et al., 2011; 21695255, Kogan et al., 2012; 22356261, Lachenmayer et al., 2012; 22811581).", "Include": "true", "ClinicalTrialNote": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT01582191", "Include": "true"}, {"nctId": "NCT03203525", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ERBB2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "ERBB2 (also known as HER2) encodes a receptor tyrosine kinase which is in the same family as EGFR. Amplification or overexpression of ERBB2 can lead to excessive proliferation and tumor formation (Higgins and Baselga, 2011; 21965336). ERBB2 amplification has been reported in a wide range of cancers in the scientific literature (Chmielecki et al., 2015; 25480824) and in the TCGA datasets, with highest prevalence in esophageal carcinoma (15%), breast invasive carcinoma (13_14%)(Cancer Genome Atlas Network., 2012; 23000897, cBio_Ciriello et al., 2015; 26451490), stomach adenocarcinoma (13%)(Cancer Genome Atlas Research Network., 2014; 25079317), pancreatic adenocarcinoma (11%)(cBio_Witkiewicz et al., 2015; 25855536), and uterine carcinosarcoma (11%, 6/56) (cBioPortal, Oct 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). HER2 is predicted to be overexpressed (as assessed by FISH, CNV analysis, or immunohistochemistry) in 12_25% of breast cancers (Chmielecki et al., 2014; 25480824, Stern, 2012; 22461643, Jones and Buzdar, 2009; 19959074). Phosphorylated HER2 was expressed in 62.5% (55/88) of HER2_positive breast cancers (Ramic et al., 2013; 23749902). Reports on the correlation of ERBB2 amplification or HER2 overexpression with prognosis have been mixed for most diseases, including gastric, esophageal, gastroesophageal (Polkowski et al., 1999; 10340889, Haas et al., 2011; 21359545, Maresch et al., 2012; 21783379), bladder urothelial (Tsai et al., 2012; 22991510), colorectal (Martin et al., 2013; 23348520, Seo et al., 2014; 24879338, Sclafani et al., 2013; 24146218). HER2 overexpression in pancreatic carcinoma has been correlated with inferior prognosis (Harder et al., 2012; 22374460, Komoto et al., 2009; 19432892, Safran et al., 2001; 11586103, Tsiambas et al., 2006; 16685109), but ERBB2 amplification was not correlated with prognosis in two studies (Sharif et al., 2008; 18463983, Tsiambas et al., 2006; 16685109). ERBB2 amplification or expression have been associated with higher tumor grade and shorter survival in patients with endometrial adenocarcinoma (Peir\u00f3 et al., 2004; 14752523, Saffari et al., 1995; 7585656, Kudela et al., 2012; 22611955) and prostate cancer (Zhang et al., 2011; 22340411, Minner et al., 2010; 20179235). On the basis of extensive clinical evidence, ERBB2 amplification or activating mutation may predict sensitivity to therapies targeting HER2, including antibodies such as trastuzumab (Slamon et al., 2001; 11248153, Bang et al., 2010; 20728210, Chumsri et al., 2015; 26358791, Cappuzzo et al., 2006; 16775247, Falchook et al., 2013; 23328556, Mazieres et al., 2013; 23610105), pertuzumab in combination with trastuzumab (Baselga et al., 2012; 22149875, Swain et al., 2015; 25693012, Chumsri et al., 2015; 26358791, Meric_Bernstam et al., 2019; 30857956), and zanidatamab (ZW25) (Meric_Bernstam et al., 2019; ESMO Abstract 453PD), as well as antibody_directed conjugates such as ado_trastuzumab emtansine (T_DM1) (Verma et al., 2012; 23020162) and fam_trastuzumab deruxtecan (T_DXd) (Modi et al., 2020; 31825192, Shitara et al., 2020; 32469182, Li et al., 2022; 34534430, Smit et al., 2021; ESMO Abstract 1361TiP), HER2 kinase inhibitors such as tucatinib (Murthy et al., 2020; 31825569, Borges et al., 2018; 29955792, Murthy et al., 2018; 29804905, Moulder et al., 2017; 28053022), and dual EGFR/HER2 kinase inhibitors such as lapatinib (Fan et al., 2020; 32478891, Cameron et al., 2010; 20736298, Geyer et al., 2006; 17192538, Serra et al., 2013; 23950206, Ali et al., 2014; 24516025, Grellety et al., 2015; 26487584, Vornicova et al., 2014; 25085898, Ronellenfitsch et al., 2020; 32017710, Hou et al., 2020; 32405522), afatinib (Lin et al., 2012; 22418700, Schwab et al., 2014; 25268372, De Greve et al., 2015; 25682316, De Greve et al., 2012; 22325357, Li et al., 2015; 26559459, Mazieres et al., 2013; 23610105, Bedard et al., 2019; AACR Abstract CT139, Dziadziuszko et al., 2019; 30825613, Lai et al., 2019; 30685684, Liu et al., 2018; 30425522, Fang et al., 2019; 31748336, Yuan et al., 2020; 32477948), neratinib (Ben_Baruch et al., 2015; 26358790, Ma et al., 2017; 28679771, Hyman et al., 2018; 29420467, Smyth et al., 2020; 31806627, Li et al., 2020; WCLC Abstract FP14.15), dacomitinib (Kris et al., 2015; 25899785), and pyrotinib (Jiang et al., 2019; ASCO Abstract 1001, Xu et al., 2020; ASCO Abstract 1003). A Phase 1 basket trial of pyrotinib demonstrated an ORR of 17% (4/23) for ERBB2_altered solid tumors, with PRs for 1 patient each with HER2_positive salivary, biliary, ovarian, or endometrial cancers (Li et al., 2020; ASCO Abstract 3510). Patients with ERBB2_mutated non_small cell lung cancer (NSCLC) have also benefited from pyrotinib (30_53% ORR) (Wang et al., 2019; 30596880, Zhou et al. 2020; 32614698).", "Include": "true", "ClinicalTrialNote": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Fam_trastuzumab deruxtecan", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Fam_trastuzumab deruxtecan is an antibody_drug conjugate that targets the protein ERBB2/HER2 on the cell surface and delivers the cytotoxic payload DXd, which inhibits DNA topoisomerase I to induce DNA damage. Fam_trastuzumab deruxtecan is FDA approved to treat patients with HER2_positive breast cancer and gastric or gastroesophageal junction adenocarcinoma who have received prior HER2_targeted therapy. It is also approved for patients with HER2_low advanced breast cancer who have previously been treated with chemotherapy, as well as for patients with advanced ERBB2_mutated non_small cell lung cancer (NSCLC) who have received systemic therapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data in solid cancers, including breast (Modi et al., 2019; 31825192, Tamura et al., 2019; 31047803), gastric (Shitara et al., 2019; 31047804, Shitara et al., 2020; 32469182), non_small cell lung (Tsurutani et al., 2018; IASLC WCLC Abstract OA02.07, Nakagawa et al., 2021; WCLC Abstract OA04.05), and colon (Yoshino et al., 2018; ESMO Abstract 563P) cancers, ERBB2 amplification may predict sensitivity to fam_trastuzumab deruxtecan. </p> <p><b>Supporting Data:</b> Fam_trastuzumab deruxtecan has demonstrated activity in multiple ERBB2_positive cancer types. In the Phase 2 DESTINY trials, clinical benefit was observed for patients treated with fam_trastuzumab deruxtecan monotherapy who had previously treated, HER2_expressing breast (61% ORR, median PFS 16.4 months) (Modi et al., 2019; 31825192), colorectal (45% ORR, median PFS 6.9 months) (Siena et al., 2020; ASCO Abstract 4000), or gastric or gastroesophageal cancer (43% ORR, median PFS 5.6 months) (Shitara et al., 2020; 32469182), as well as HER2_mutated lung cancer (62% ORR, median PFS 14.0 months) (Smit et al., 2020; ASCO Abstract 9504). Benefit was also observed in a Phase 2 trial for ERBB2_expressing biliary tract cancer (30% ORR) (Ohba et al., 2020; ASCO Abstract 4006). In a Phase 1 study evaluating single_agent fam_trastuzumab deruxtecan for the treatment of patients with ERBB2_mutated solid tumors or ERBB2_expressing solid tumors other than breast or gastric cancer, the median PFS was 7.2 months and the ORR was 28% (17/60), with responses reported for patients with non_small cell lung carcinoma (NSCLC), breast cancer, colorectal cancer (CRC), salivary gland carcinoma, cholangiocarcinoma, and endometrial cancer (Tsurutani et al., 2020; 32213540). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Lapatinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Lapatinib is a tyrosine kinase inhibitor that targets EGFR, ERBB2/HER2, and to a lesser degree, ERBB4. It is FDA approved in combination with capecitabine to treat patients with HER2_overexpressing (HER2+) metastatic breast cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Activation or amplification of ERBB2 may predict sensitivity to lapatinib (Cameron et al., 2010; 20736298, Geyer et al., 2006; 17192538, Serra et al., 2013; 23950206, Ali et al., 2014; 24516025, Grellety et al., 2015; 26487584, Fan et al., 2020; 32478891, Vornicova et al., 2014; 25085898, Ronellenfitsch et al., 2020; 32017710, Hou et al., 2020; 32405522). </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of lapatinib have primarily been in the context of breast cancer (Geyer et al., 2006; 17192538, Cameron et al., 2010; 20736298, Bian et al., 2013; 23729232, Baselga et al., 2012; 22257673, Robidoux et al., 2013; 24095300, Alba et al., 2014; 24457911, Gelmon et al., 2015; 25779558, Verma et al., 2012; 23020162). Phase 3 and Phase 2 studies have reported clinical activity of lapatinib plus chemotherapy combinations for HER2+ advanced gastric (Satoh et al., 2014; 24868024), gastroesophageal (Lorenzen et al., 2015; 25694417, Galsky et al., 2012; 20857170), and upper gastrointestinal tract (Hecht et al., 2016; 26628478) cancer. Additionally, Phase 1 studies evaluating lapatinib alone or in combination with chemotherapy agents reported PRs in patients with various solid tumors and 1 CR in a patient with EGFR_overexpressing head and neck squamous cell carcinoma (Burris et al., 2009; 19825948, Chu et al., 2007; 17704424, Chew et al., 2011; 21778300, Siegel_Lakhai et al., 2007; 17671135). In a Phase 1 trial of lapatinib plus pazopanib, one patient with a salivary gland tumor experienced a PR (Tan et al., 2014; 24800949). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Ado_trastuzumab emtansine", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Ado_trastuzumab emtansine (T_DM1) is an antibody_drug conjugate that targets the protein ERBB2/HER2 on the cell surface, which inhibits HER2 signaling; it also releases the cytotoxic therapy DM1 into cells, leading to cell death. T_DM1 is FDA approved to treat patients with HER2_positive (HER2+) metastatic breast cancer and disease progression on prior therapy as well as patients with HER2+ early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab_based treatment. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ERBB2 amplification or activating mutations may predict sensitivity to T_DM1 (Jhaveri et al., 2019; 31504139, Li et al., 2018; ASCO Abstract 2502, Li et al., 2020; 32213539, Hotta et al., 2018; 29313813, Krop et al., 2014; 24793816, Verma et al., 2012; 23020162, Welslau et al., 2014; 24222194, Krop et al., 2012; 22649126, Burris et al., 2011; 21172893, Jhaveri et al., 2018; ASCO Abstract 100, Baselga et al., 2016; 26920887, Perez et al., 2016; 28056202, Hurvitz et al., 2013; 23382472, von Minckwitz et al., 2019; 30516102, Hurvitz et al., 2019; 31157583, Martin et al., 2016; 27052654, Mondaca et al., 2019; 32923849). </p> <p><b>Supporting Data:</b> The vast majority of data on the therapeutic use of T_DM1 have been collected in the context of breast cancer, although clinical trials investigating T_DM1 are underway in several tumor types, primarily in HER2+ cancers. Phase 2 basket trials for HER2_amplified cancers have reported ORR of 8_28% with T_DM1, including responses in salivary gland, lung, endometrial, biliary tract, and ovarian cancers (Li et al., 2018; ASCO Abstract 2502)(Jhaveri et al., 2018; ASCO Abstract 100). A Phase 3 trial in 602 patients with HER2+ breast cancer reported that those who received T_DM1 showed an improved progression_free survival (PFS) and a lower rate of adverse events than patients who received the physician\u2019s choice of therapy (Krop et al., 2014; 24793816). A second Phase 3 trial in 991 patients with HER2+ breast cancer reported that T_DM1 brought about significantly longer overall survival (OS) and PFS, as compared with lapatinib plus capecitabine, in patients previously treated with trastuzumab plus a taxane (Verma et al., 2012; 23020162, Welslau et al., 2014; 24222194). Two separate Phase 2 trials reported robust activity for single_agent T_DM1 as a treatment for HER2+ metastatic breast cancer in patients previously treated with standard HER2_directed therapies or HER2_directed therapies plus chemotherapy, with objective response rates of 34.5% and 25.9%, respectively, and PFS of 6.9 months and 4.9 months, respectively (Krop et al., 2012; 22649126, Burris et al., 2011; 21172893). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Margetuximab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Margetuximab is an Fc_engineered antibody targeting ERBB2/HER2 that was designed to enhance the anti_tumor immune response. Margetuximab is FDA approved for the treatment of patients with HER2_positive breast cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical studies in multiple tumor types, ERBB2 amplification may predict sensitivity to margetuximab (Rugo et al., 2019; ASCO Abstract 1000, Bang et al., 2017; 28119295, Burris et al., 2013; ASCO Abstract 3004, Catenacci et al., 2019; ESMO Abstract 2812). </p> <p><b>Supporting Data:</b> The Phase 3 SOPHIA trial of margetuximab for HER2+ metastatic breast cancer reported improved median PFS (5.8 vs. 4.9 months, HR=0.76) and ORR (22% vs. 16%) when combining margetuximab with chemotherapy, compared with trastuzumab and chemotherapy, for patients who had progressed on \u22652 prior HER2_directed therapies (Rugo et al., 2019; ASCO Abstract 1000); however, median OS was not statistically different between the 2 treatment arms (21.6 vs. 21.9 months, HR=0.62) (Rugo et al., 2021; SABCS Abstract PD8_01). In a Phase 1 trial for HER2_overexpressing solid tumors, 12% (7/60) of patients, including 4 with breast, 2 with gastroesophageal, and 1 with lacrimal gland cancers, experienced PRs, and a further 52% (31/60) of the cohort experienced SD (Bang et al., 2017; 28119295). In a study of margetuximab for HER2+ cancers, a patient with salivary gland cancer reported a PR (Burris et al., 2013; ASCO Abstract 3004). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Trastuzumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Trastuzumab is a monoclonal antibody that targets the protein ERBB2/HER2. It is FDA approved as monotherapy and in combination with chemotherapy for HER2+ metastatic gastric or gastroesophageal adenocarcinoma. Trastuzumab biosimilars are also FDA approved for these indications. Please see the drug label(s) for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical studies in multiple tumor types, ERBB2 amplification, overexpression, or activating mutations may confer sensitivity to trastuzumab (Gianni et al., 2014; 24657003, Morris et al., 2013; 24037735, Hainsworth et al., 2018; 29320312, Mazi\u00e8res et al., 2013; 23610105, Ali et al., 2014; 24516025, Wang et al., 2016; 27334835, Nishikawa et al., 2017; 27521503, Bang et al., 2010; 20728210, Slamon et al., 2001; 11248153). </p> <p><b>Supporting Data:</b> The majority of data investigating the therapeutic use of trastuzumab has been in the context of breast cancer. Trastuzumab was approved for breast cancer on the basis of a Phase 3 randomized clinical trial comparing treatment with trastuzumab and chemotherapy to treatment with chemotherapy alone. The addition of trastuzumab was associated with significant improvements in time to progression, objective response rate, response duration, and overall survival (Slamon et al., 2001; 11248153). A subsequent Phase 3 study of patients with HER2_positive (HER2+) breast cancer reported 5_year event_free survival in 58% of patients treated with trastuzumab plus neoadjuvant therapy, compared to 43% in patients treated with neoadjuvant therapy alone (Gianni et al., 2014; 24657003). Long_term follow_up Phase 2 analysis reported a 5_year distant disease_free survival rate of 92% in patients with HER2+ breast cancer treated with dose_dense chemotherapy and trastuzumab and 89% in patients treated with lapatinib and dose_sense chemotherapy (Morris et al., 2013; 24037735). A Phase 3 trial of patients with HER2+ breast cancer treated with lapatinib, trastuzumab, or a combination of the two, reported event_free survival rates of 78%, 76%, and 84%, and overall survival of 93%, 90%, and 95%, respectively (de Azambuja et al., 2014; 25130998). In a Phase 2 study of 14 patients with salivary gland carcinoma with overexpressed HER2 protein, trastuzumab had low activity, with a median time to progression of 4.2 months (Haddad et al., 2003; 12907212). A retrospective study of patients with HER2_positive salivary duct carcinoma reported that 62% (5/8) of patients who received adjuvant therapy including chemotherapy with paclitaxel, carboplatin, and trastuzumab (TCH) exhibited no evidence of disease after more than 24 months and 100% (5/5) of patients with metastatic disease exhibited response to TCH (Limaye et al., 2013; 23429737). Trastuzumab was approved in combination with cisplatin and 5_fluorouracil or capecitabine for (HER2+) metastatic gastric or gastroesophageal junction adenocarcinoma in the first line treatment setting based upon improvement in survival observed in the ToGA trial (Bang et al., 2010; 20728210). A Phase 1/2 trial of trastuzumab in patients with HER2+ esophageal adenocarcinoma and co_treated with cisplatin, paclitaxel and radiotherapy reported a median survival of 24 months with a two_year survival rate of 50% (Safran et al., 2007; 17097832). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Trastuzumab + Pertuzumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Trastuzumab is a monoclonal antibody that targets ERBB2/HER2, and pertuzumab is a monoclonal antibody that interferes with the interaction between HER2 and ERBB3. These therapies are FDA approved in combination for the treatment of patients with HER2_positive (HER2+) metastatic breast cancer who have not received prior chemotherapy or HER2_targeted therapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical studies in multiple tumor types, ERBB2 amplification or activating mutations may predict sensitivity to trastuzumab in combination with pertuzumab (Hurvitz et al., 2017; 29175149, von Minckwitz et al., 2017; 28581356, Hainsworth et al., 2018; 29320312, Swain et al., 2015; 25693012, Swain et al., 2018; 29253081, Gianni et al., 2016; 27179402, Shao et al., 2020; 31647503). </p> <p><b>Supporting Data:</b> The Phase 2 MyPathway basket trial for patients with HER2_positive solid tumors treated with trastuzumab plus pertuzumab reported a 23% ORR (60/258), a 45% DCR (115/258), a 7.9 month median duration of response, 2.8 months mPFS, and 10.9 months mOS; clinical responses were observed across multiple tumor types, including CRC, lung, urothelial, biliary, and ovarian (Hainsworth et al., 2018; 2932031, Meric_Bernstam et al., 2019; 30857956, Meric_Bernstam et al., 2021; ASCO Abstract 3004). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Dacomitinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Dacomitinib is a second generation irreversible tyrosine kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4/HER4. It is FDA approved for the first_line treatment of patients with metastatic non_small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Prospective early_phase single_arm clinical trials report anti_tumor activity of dacomitinib in advanced solid tumors with ERBB2 activating mutations (Kris et al., 2015; 25899785, Janne et al., 2011; 21220471), ERBB2 amplification (Kim et al., 2015; 25424851, Reckamp et al., 2014; 24501009), or HER2 overexpression (Oh et al., 2016; 26581547). </p> <p><b>Supporting Data:</b> Investigations into the efficacy of dacomitinib have primarily been in the context of non_small cell lung cancer (NSCLC). Patients with EGFR_mutant NSCLC treated with dacomitinib exhibited significant improvement in OS compared with gefitinib treatment (median OS, 34.1 vs. 26.8 months) (Mok et al., 2018; 2986437, Wu et al., 2017; 28958502). A Phase 2 study of dacomitinib in patients with advanced penile squamous cell carcinoma (SCC) reported an ORR of 32% (1 CR, 8 PR), including a 100% DCR (1 CR, 1 PR, 2 SD) in four patients with EGFR amplification (Necchi et al., 2018; ASCO Abstract 399)(Necchi et al., 2018; 28921872). A Phase 2 study of dacomitinib in patients with recurrent or metastatic head and neck SCC reported clinical benefit (defined as PFS>4 months) in 13/31 (42%) of patients (Kim et al., 2015; 25424851). Studies of dacomitinib in esophageal (Kim et al., 2015; 26462025) and cutaneous (Cavalieri et al., 2018; 29734047) SCC reported RRs of 12.5% (6/48) and 28.6% (12/42), respectively, but high DCRs of 73% and 86%, respectively. In contrast, trials of dacomitinib in heavily pretreated patients with HER2+ gastric cancer (Oh et al., 2016; 26581547) and patients with EGFR_amplified glioblastoma (Sepulveda_Sanchez et al, 2017; 28575464) found RRs of fewer than 10% and DCRs of fewer than 50%: 11/27 (41%) DCR in HER2+ gastric cancer (Oh et al., 2016; 26581547) and 15/49 (31%) in EGFR_amplified glioblastoma (Sepulveda_Sanchez et al, 2017; 28575464). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Neratinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Neratinib is an irreversible tyrosine kinase inhibitor that targets EGFR, ERBB2/HER2, and ERBB4. It is FDA approved for the extended adjuvant treatment of early_stage HER2_positive (HER2+) breast cancer following adjuvant trastuzumab. Neratinib is also approved in combination with capecitabine to treat patients with advanced or metastatic HER2+ breast cancer who have been previously treated with 2 or more anti_HER2 regimens. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of extensive clinical (Li et al., 2020; WCLC Abstract FP14.15, Ma et al., 2017; 28679771, Chan et al., 2016; 26874901, Ben_Baruch et al., 2015; 26358790, Park et al., 2016; 27406346, Hyman et al., 2018; 29420467, Smyth et al., 2020; 31806627) and preclinical (Schwab et al., 2015; 26260909, Menderes et al., 2017; 28397106, Hu et al., 2015; 26375550, Kavuri et al., 2015; 26243863, Bose et al., 2013; 23220880) evidence, ERBB2 amplification or activating mutations may confer sensitivity to neratinib. </p> <p><b>Supporting Data:</b> Neratinib has been largely evaluated in the context of breast cancer and non_small cell lung cancer (NSCLC). For patients with advanced HER2_positive breast cancer, neratinib treatment resulted in PFS of 22.3 weeks for patients with prior trastuzumab treatment and 39.6 weeks for those with no prior trastuzumab treatment (Burstein et al., 2010; 20142587). In patients with HER2_positive breast cancer with brain metastases, neratinib elicited a CNS ORR of 8% (3/40) (Freedman et al., 2016; 26834058). In a Phase 3 study of patients with HER2_positive, early stage breast cancer previously treated with trastuzumab, neratinib significantly improved the 2_year invasive disease_free survival compared to placebo (HR=0.67, p=0.0091)(Chan et al., 2016; 26874901). In Phase 2 trials of single_agent neratinib for patients with ERBB2_mutated, non_amplified metastatic breast cancer, clinical benefit rates of 31_40% and median PFS of 3.5_4 months have been achieved (Ma et al., 2017; 28679771, Hyman et al., 2018; 29420467, Smyth et al., 2019; 31806627). Neratinib in combination with various other agents has also shown significant clinical activity against breast cancer (Hyman et al., 2016; SABCS Abstract PD2_08)(Saura et al., 2014; 25287822, Awada et al., 2012; 22967996, Martin et al., 2013; 23953056, Chow et al., 2013; 23632474, Park et al., 2016; 27406346, Awada et al., 2016; 27078022). In patients with ERBB2_mutated NSCLC, where the majority of cases harbor inhibitor_resistant exon 20 insertions, neratinib monotherapy has resulted in ORRs of 0_4% (Gandhi et al. 2017; WCLC Abstract MA04.02, Gandhi et al., 2014; 24323026, Hyman et al., 2018; 29420467, Li et al., 2020; WCLC Abstract FP14.15). However, clinical outcomes have been improved by combination of neratinib with other targeted agents, such as temsirolimus or trastuzumab (Gandhi et al., 2014; 24323026, Gandhi et al. 2017; WCLC Abstract MA04.02, Li et al., 2020; WCLC Abstract FP14.15). Trials of neratinib have shown high ORRs (up to 44%) in ERBB2_mutated cervical cancer (Hyman et al., 2018; 29420467, D Souza et al., 2019; SGO Abstract 18) but very low ORRs in colorectal and bladder cancer (Hyman et al., 2018; 29420467). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Afatinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Afatinib is an irreversible kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4. It is FDA approved for the first_line treatment of patients with metastatic non_small cell lung cancer (NSCLC) and nonresistant EGFR mutations and for the treatment of patients with metastatic, squamous NSCLC after progression on platinum_based chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Clinical and preclinical data support sensitivity of ERBB2 amplification (Talwar and Cohen, 2012; 24371631, Choudhury et al., 2016; 27044931, Kwak et al., 2013; 23775486, Schwab et al., 2014; 25268372), or HER2 overexpression (Lin et al., 2012; 22418700, Rimawi et al., 2015; 25537159, Gunzer et al., 2016; 26835225, Janjigian et al., 2013; 23578997), to afatinib. </p> <p><b>Supporting Data:</b> Afatinib has been primarily evaluated for the treatment of EGFR_mutant NSCLC, in which treatment with afatinib exhibited significant improvement in progression free survival (PFS) vs. chemotherapy treatments (Sequist et al., 2013; 23816960, Katakami et al., 2013; 23816963). A Phase 2 trial of afatinib in patients with either EGFR or ERBB2 amplification and esophagogastric, biliary tract, urothelial tract, or gynecologic cancer reported a 5% (1/20) objective response rate, with complete response achieved in one patient and stable disease (SD) achieved in 8 patients; the authors concluded that afatinib activity as a single agent was encouraging (Kwak et al., 2013; 23775486). A Phase 1 trial of afatinib in advanced cancer reported SD in 14/31 patients (Marshall et al., 2013; 23414476). A Phase 1 study of afatinib combined with pemetrexed in patients with advanced solid tumors reported confirmed partial response in 3% (1/30) of patients and SD in 33% (10/30) of patients (Chu et al., 2013; ASCO Abstract 2523). Outcomes of partial response and/or stable disease have been reported in various clinical trials involving multiple cancer types, including HER2_positive breast cancer, NSCLC, colorectal cancer, and esophageal cancer (Sequist et al., 2013; 23816960, De Gr\u00e8ve et al., 2012; 22325357, Katakami et al., 2013; 23816963, Yap et al., 2010; 20679611, Eskins et al., 2008; 18026190). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04644068", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT03498521", "Include": "true"}, {"nctId": "NCT04579380", "Include": "true"}, {"nctId": "NCT04162327", "Include": "true"}, {"nctId": "NCT04040699", "Include": "true"}, {"nctId": "NCT05159245", "Include": "true"}, {"nctId": "NCT02693535", "Include": "true"}, {"nctId": "NCT04983238", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": [{"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). In the TCGA datasets, concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in several tumor types, with the highest incidences in glioblastoma multiforme (54%), mesothelioma (45%), esophageal adenocarcinoma (39%), bladder urothelial carcinoma (31%), melanoma (31%), and HNSCC (30%) cases (cBioPortal, Mar 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In addition, mutation of CDKN2A has been reported in 45% of cutaneous SCC (Li et al., 2015; 25589618), 21% of HNSCC (HNSCC_Cancer Genome Atlas Network., 2015; 25631445), 17% of lung SCC (Cancer Genome Atlas Research Network., 2012; 22960745), and 3_4.5% of esophageal SCC (cBio_Song et al., 2014; 24670651, cBio_Lin et al., 2014; 24686850) cases. Loss of p16INK4a expression has been reported in 67_80% of pancreatic ductal adenocarcinomas (Oshima et al., 2013; 23470568, Tsiambas et al., 2007; 17600882) and in 59% of NSCLCs (Yanagawa et al., 2013; 23254264). Inactivation of CDKN2A and/or CDKN2B and loss of p16INK4a and/or p15INK4b protein expression have been correlated with poor patient prognosis in several tumor types, including pancreatic ductal adenocarcinoma, gastric cancer, and lung cancer (Chang et al., 2010; 20665497, Oshima et al., 2013; 23470568, Lee et al., 2002; 12060614, Hu et al., 2010; 21302620, Shi et al., 2012; 22206050, Bradly et al., 2012; 23111194, Lou_Qian et al., 2013; 23372805, Tan et al., 2013; 23614702). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "CDKN2B loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2B loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). In the TCGA datasets, concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in several tumor types, with the highest incidences in glioblastoma multiforme (54%), mesothelioma (45%), esophageal adenocarcinoma (39%), bladder urothelial carcinoma (31%), melanoma (31%), and HNSCC (30%) cases (cBioPortal, Mar 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In addition, mutation of CDKN2A has been reported in 45% of cutaneous SCC (Li et al., 2015; 25589618), 21% of HNSCC (HNSCC_Cancer Genome Atlas Network., 2015; 25631445), 17% of lung SCC (Cancer Genome Atlas Research Network., 2012; 22960745), and 3_4.5% of esophageal SCC (cBio_Song et al., 2014; 24670651, cBio_Lin et al., 2014; 24686850) cases. Loss of p16INK4a expression has been reported in 67_80% of pancreatic ductal adenocarcinomas (Oshima et al., 2013; 23470568, Tsiambas et al., 2007; 17600882) and in 59% of NSCLCs (Yanagawa et al., 2013; 23254264). Inactivation of CDKN2A and/or CDKN2B and loss of p16INK4a and/or p15INK4b protein expression have been correlated with poor patient prognosis in several tumor types, including pancreatic ductal adenocarcinoma, gastric cancer, and lung cancer (Chang et al., 2010; 20665497, Oshima et al., 2013; 23470568, Lee et al., 2002; 12060614, Hu et al., 2010; 21302620, Shi et al., 2012; 22206050, Bradly et al., 2012; 23111194, Lou_Qian et al., 2013; 23372805, Tan et al., 2013; 23614702). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "FANCC", "Include": "true", "Alterations": {"Alteration": {"Name": "Q485fs*2", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q485fs*2"}}, "Interpretation": "FANCC encodes a key component of an eight protein (FANCA/B/C/E/F/G/L/M) Fanconi anemia (FA) nuclear E3 ubiquitin ligase complex. This complex is involved in DNA repair and is essential for prevention of chromosome breakage caused by DNA damage (Moldovan and D\u2019Andrea, 2009; 19686080). Upon DNA damage or during the S_phase of the cell cycle, the FA complex is activated and recruited to the sites of DNA damage/DNA repair. The complex then activates FANCD2 and FANCL via monoubiquitination, leading to their co_localization with FANCD1/BRCA2, BRCA1, RAD51, PCNA, and other proteins at the DNA repair foci on chromatin. Germline mutations in FANCC cause Fanconi anemia, a clinically heterogeneous disorder involving various developmental abnormalities as well as predisposition to cancer; underlying these phenotypes are defects in DNA repair (Deakyne and Mazin, 2011; 21568838). Somatic mutations in FANCC are very infrequently observed in human malignancies (COSMIC, Jan 2022)(Tate et al., 2019; 30371878). There are no targeted therapies that directly address loss of FANCC activity. However, limited preclinical evidence (Ghosh et al., 2014; 24200853, Lombardi et al., 2015; 25609062) and clinical evidence in sarcoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096) suggest that FANCC alterations may predict sensitivity to PARP inhibitors.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FH", "Include": "true", "Alterations": {"Alteration": {"Name": "A273T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "A273T"}}, "Interpretation": "FH encodes fumarate hydratase, an enzymatic component of the Krebs cycle. FH has been identified as a possible hypoxia inducible factor activating gene (Morris et al., 2004; 15220362). Loss_of_function germline mutations in FH are associated with hereditary leiomyomatosis and renal cell cancer (HLRCC); tumors arising in FH mutation carriers often demonstrate FH biallelic inactivation (Schmidt et al., 2020; 31085323, Lehtonen et al., 2006; 16155190, Tomlinson et al., 2002; 11865300, Gardie et al., 2011; 21398687). FH mutations have been detected in several tumor types, with the highest incidences reported in tumors of the endometrium (2.6%), skin (2.3%), liver (1.7%), stomach (1.5%), and lung (1.4%)(COSMIC, Jan 2022)(Tate et al., 2019; 30371878). FH_deficient renal cell carcinoma (RCC) arises in about 20% of families affected by hereditary leiomyomatosis and renal cell cancer (HLRCC) and is associated with aggressive disease and poor prognosis (Schmidt et al., 2020; 31085323, Lau et al., 2020; 31524643, Gardie et al., 2011; 21398687). A preclinical study showed that FH_deficient renal cancer cells are dependent on ABL1 activity and sensitive to the multikinase inhibitor vandetanib; treatment with vandetanib inhibited the growth and tumorigenicity of these cells in vitro and in vivo (Sourbier et al., 2014; 25490448). Tumors with FH loss or inactivation may therefore be sensitive to vandetanib, which is approved to treat medullary thyroid cancer and is in clinical trials in solid tumors. A Phase 2 trial of bevacizumab and erlotinib reported overall response rate in 60% (12/20) of patients with hereditary leiomyomatosis and renal cell cancer, and 29% (6/21) of patients with sporadic papillary renal cell carcinoma (Srinivasan et al., 2014; EORTC_NCI_AACR Abstract 5). FH germline inactivating alterations are associated with FH tumor predisposition syndrome, also known as hereditary leiomyomatosis and renal cell cancer (HLRCC), an autosomal_dominant syndrome characterized by cutaneous leiomyomata, uterine fibroids, and aggressive renal cell carcinoma (RCC) (Tomlinson et al., 2002; 11865300). Pheochromocytoma and paraganglioma have also been described at lower frequency (Castro_Vega et al., 2014; 24334767, Muller et al., 2017; 28300276). Whereas cutaneous leiomyomata appear at a mean age of 30 years, increasing in size and number with age, the age at diagnosis of uterine fibroids ranges from 18 to 53 years (Muller et al., 2017; 28300276, Lehtonen, et al., 2011; 21404119). HLRCC has been associated with a 21% lifetime risk of RCC (Forde et al., 2020; 31831373). In the appropriate clinical context, germline testing of FH is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MAP2K4", "Include": "true", "Alterations": {"Alteration": {"Name": "Q327*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q327*"}}, "Interpretation": "MAP2K4 encodes the protein kinase MKK4, a member of a MAPK signaling cascade that leads to apoptosis in response to cellular stress (Curtis et al., 2012; 22522925). MAP2K4 has been proposed to act as a tumor suppressor in several cancer types, including pancreatic cancer, but has also been suggested to act as an oncogene in certain situations (Teng et al., 1997; 9331070, Curtis et al., 2012; 22522925, Ahn et al., 2011; 21896780, Davis et al., 2011; 21575258, Lee et al., 2005; 16115952, Lee et al., 2003; 12714585, Cunningham et al., 2006; 16740690). Alterations such as seen here may disrupt MAP2K4 function or expression (Ahn et al., 2011; 21896780, Kan et al., 2010; 20668451, Teng et al., 1997; 9331070, Takekawa et al., 2005; 15866172, Young_Ho et al., 2011; 21896780). MAP2K4 mutations have been reported at highest frequencies in liver (4.3%), endometrial (3.8%), breast (3.7%), pancreatic (3.5%), biliary tract (3.5%), and gastric (3.3%) carcinomas (COSMIC, Feb 2022)(Tate et al., 2019; 30371878). MAP2K4 homozygous deletion has been observed in multiple tumor types, including stomach adenocarcinoma (3.4%), ovarian serous cystadenocarcinoma (2.6%), breast invasive carcinoma (2.3%), pancreatic adenocarcinoma (2.2%), and colorectal adenocarcinoma (1.9%)(cBioPortal, Feb 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Loss of MKK4 expression has been linked to tumor cell invasion, metastasis, and poor prognosis in some cancer types (Ahn et al., 2011; 21896780, Davis et al., 2011; 21575258, Ishikawa et al., 2010; 21372598, Hickson et al., 2006; 16489030). There are no therapies available to target MAP2K4 loss or inactivation. However, a preclinical study reported that inactivation of MAP2K4 may confer sensitivity to MEK inhibitors (Xue et al., 2018; 29795445).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "G244V", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "G244V"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Pan_cancer analysis of the TCGA datasets across 12 cancer types identified TP53 as the most frequently mutated gene, with 42% of more than 3,000 tumors harboring a TP53 mutation; in this study TP53 mutation occurred most frequently in ovarian serous carcinoma (95%), lung squamous cell carcinoma (SCC) (79%), head and neck SCC (70%), colorectal adenocarcinoma (59%), lung adenocarcinoma (52%), and bladder urothelial carcinoma (50%) (Kandoth et al., 2013; 24132290). TP53 loss of heterozygosity (LOH) is frequently seen in tumors and often occurs when one copy of TP53 harbors a mutation; in some tumors, LOH is correlated with progression (Wongsurawat et al., 2006; 16537709, Brosh and Rotter, 2009; 19693097, Baker et al., 1989; 2649981, Calcagno et al., 2013; 24053468). While the prognostic significance of TP53 alteration or dysregulation varies according to tumor type, studies have shown an association with poor prognosis for patients with breast cancer (Alsner et al., 2008; 18465328, Olivier et al., 2006; 16489069, V\u00e9gran et al., 2013; 23359294), endometrial cancer (Wild et al., 2012; 22678923, Lee et al., 2010; 20006376), HNSCC (Ganci et al., 2013; 24107801, Lindenbergh_van et al., 2011; 21467160, Peltonen et al., 2011; 21513535), or urothelial cancer (Bringuier et al., 1998; 9761125, Feng et al., 2014; 24500328). In one study of 55 patients with lung adenocarcinoma, TP53 alterations correlated with immunogenic features including PD_L1 expression, tumor mutation burden and neoantigen presentation; likely as a consequence of this association TP53 mutations correlated with improved clinical outcomes to PD_1 inhibitors pembrolizumab and nivolumab in this study (Dong et al., 2016; 28039262). TP53 mutation has not been consistently demonstrated to be a significant independent prognostic marker in the context of CRC (Russo et al., 2005; 16172461, Fong et al., 2022; ASCO GI Abstract 57). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Carcinomas that have been reported to harbor the highest frequencies of elevated TMB include colorectal (CRC) (8_25%) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117), endometrial (7_24%) (Frampton et al., 2016; ASCO Abstract 11558, Santin et al., 2016; ASCO Abstract 414, Cancer Genome Atlas Research Network., 2013; 23636398), intestinal type gastric (20%) (Frampton et al., 2016; ASCO Abstract 11558), and non_small cell lung carcinoma (NSCLC; 8_13%) (Spigel et al., 2016; ASCO Abstract 9017, Jiang et al., 2016; ASCO Abstract e23128). In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis (Xiao et al., 2016; 27009843), as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high_TMB samples each), but not BRAF (10.3%) or KRAS (9.4%) (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and increased TMB in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong link (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117) and with microsatellite instability (MSI) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117), which in turn has been reported to correlate with better prognosis (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network., 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559) and bladder cancer (Cazier et al., 2016; 24777035), it is also linked with improved prognosis in patients with these tumor types (Rosenberg et al., 2016; ASCO Abstract 104, Cancer Genome Atlas Research Network., 2013; 23636398). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "VEGFA", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "VEGFA (vascular endothelial growth factor A) encodes a ligand that promotes angiogenesis through the receptor tyrosine kinases VEGFR1 and VEGFR2 (Goel and Mercurio., 2013; 24263190). VEGFA promotes tumor growth by activating both autocrine VEGFR signaling in tumor cells and paracrine signaling to fibroblasts and immune cells in the tumor microenvironment (Goel and Mercurio., 2013; 24263190). VEGFA has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and is associated with response to sorafenib (Horwitz et al., 2014; 24687604). In the TCGA datasets, VEGFA amplification was observed in 13% of esophageal carcinoma, 7% of stomach adenocarcinoma, 3% of lung adenocarcinoma, 2% of pancreatic adenocarcinoma, and 1% of colorectal adenocarcinoma (CRC) cases (Cancer Genome Atlas Research Network., 2014; 25079317, Cancer Genome Atlas Research Network., 2014; 25079552, Cancer Genome Atlas Network., 2012; 22810696). Amplification of the 6p12 locus, where VEGFA is located, has been observed in 3% of CRC cases (Vlajnic et al., 2011; 21743435). Increased plasma VEGF_A levels have been associated with decreased overall survival in patients with non_small cell lung cancer (NSCLC) (Mok et al., 2014; 24807156, Hegde et al., 2013; 23169435) and with worse prognosis in patients with cervical cancer (Du et al., 2014; 25374209), and VEGF expression was reported to be correlated with higher stage in hypopharyngeal SCC (Hong et al., 2014; 25158264). There have been conflicting reports regarding the value of serum VEGF_A levels as a prognostic indicator in patients with gastric cancer (Van Cutsem et al., 2012; 22565005, Park do et al., 2014; 24370903), gastroesophageal junction cancer (Park do et al., 2014; 24370903), non_small cell lung cancer (NSCLC) (Mok et al., 2014; 24807156, Hegde et al., 2013; 23169435), pancreatic ductal adenocarcinoma (Chang et al., 2008; 18665074, Georgiadou et al., 2014; 24480377, Rahbari et al., 2011; 21729304); furthermore, it has not been shown that VEGFA amplification or expression in tumor cells results in increased plasma levels of VEGF_A (Mok et al., 2014; 24807156). The approved VEGFA_targeted agents bevacizumab and ziv_aflibercept have demonstrated efficacy in multiple tumor types; however, expression or amplification of VEGFA has not been established as a reliable biomarker of response to these therapies (Van Cutsem et al., 2012; 22565005, Miles et al., 2013; 23422754, Gianni et al., 2013; 23569311, Cameron et al., 2013; 23932548, Hegde et al., 2013; 23169435, Schneider et al., 2012; 23340303, Baumgarten et al., 2016; 26627848, Sathornsumetee et al., 2008; 18182667, Olafson et al., 2019; 31582283, Nishikawa et al., 2013; ASCO Abstract 2023, Wick et al., 2013; WCN Abstract 1207, Duda et al., 2010; 20484123, Stremitzer et al., 2016; 27535973, Weickhardt et al., 2015; 26125443, Kopetz et al., 2009; 20008624, Fountzilas et al., 2011; 21868552, S\u00e1nchez_Rovira et al., 2013; 23397155, Mok et al., 2014; 24807156, An et al., 2014; 24577128, Bais et al., 2017; 29059426, Van Cutsem et al., 2011; EMCC Abstract 803, Xu et al., 2009; 19826039, Hasselbalch et al., 2010; 20666740, Marisi et al., 2017; 28465540, Jubb et al., 2005; 16365183, Goede et al., 2010; 20924372, Bruhn et al., 2013; 24374727, Escudier et al., 2007; 18156031, Yang et al., 2003; 12890841, Burstein et al., 2008; 19047116, Jubb et al., 2011; 21224365, Miles et al., 2017; 27817944, Dowlati et al., 2008; 18316562, Horn et al., 2009; 19826110, Blakeley et al., 2016; 26976425). Preclinical hepatocellular carcinoma (HCC) models with VEGFA amplification showed increased sensitivity to sorafenib, and a small retrospective study reported significantly increased OS for 7 patients with VEGFA_amplified HCC treated with sorafenib (Horwitz et al., 2014; 24687604). However, a prospective biomarker study showed that VEGFA amplification detected by circulating cell_free DNA was not significantly associated with DCR, time to progression, or median OS for patients with HCC treated with first_line sorafenib (Oh et al., 2019; 30935424). It is currently not known if VEGFA amplification predicts response to other inhibitors targeting VEGFRs.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "CTNNB1", "Alteration": "S45P", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "S45P", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "S45P", "Title": "A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, SRC, RET, VEGFRs", "Locations": "Texas", "NCTID": "NCT01582191", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "S45P", "Title": "Combination Chemotherapy and Bevacizumab With the NovoTTF_100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer", "StudyPhase": "PHASE 1", "Target": "VEGFA, mTOR", "Locations": "Texas", "NCTID": "NCT03203525", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Include": "true"}, {"Gene": "ERBB2", "Alteration": "amplification", "Title": "Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies", "StudyPhase": "PHASE 1/2", "Target": "ERBB2, TROP2, PARP", "Locations": "Shanghai (China), Seoul (Korea, Republic of), Chongqing (China), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary)", "NCTID": "NCT04644068", "Note": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Include": "true"}, {"Gene": "ERBB2", "Alteration": "amplification", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Include": "true"}, {"Gene": "ERBB2", "Alteration": "amplification", "Title": "A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum_Based Chemotherapy in Patients With Cancer of Unknown Primary Site", "StudyPhase": "PHASE 2", "Target": "ALK, RET, SMO, AKTs, PARP, PD_L1, EGFR, VEGFA, MEK, BRAF, ERBB2, TRKB, TRKC, ROS1, TRKA", "Locations": "Fukuoka (Japan), Ehime (Japan), Seoul (Korea, Republic of), Aichi (Japan), Tokyo (Japan), Chiba (Japan), Bangkok (Thailand), South Brisbane (Australia), Bedford Park (Australia), Blacktown (Australia)", "NCTID": "NCT03498521", "Note": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Include": "true"}, {"Gene": "ERBB2", "Alteration": "amplification", "Title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations", "StudyPhase": "PHASE 2", "Target": "ERBB2, ER", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Osakasayama (Japan), Nagoya_shi (Japan), Kawasaki_shi (Japan), Chuo_Ku (Japan), Tokyo (Japan), Kashiwa_shi (Japan), Poznan (Poland), Amsterdam (Netherlands)", "NCTID": "NCT04579380", "Note": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Include": "true"}, {"Gene": "ERBB2", "Alteration": "amplification", "Title": "A Phase Ia/Ib Study of IBI315 in Patients With HER2_expressing Advanced Solid Tumor", "StudyPhase": "PHASE 1", "Target": "ERBB2, PD_1", "Locations": "Beijing (China)", "NCTID": "NCT04162327", "Note": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Include": "true"}, {"Gene": "ERBB2", "Alteration": "amplification", "Title": "KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor", "StudyPhase": "PHASE 1", "Target": "ERBB2, CTLA_4, PD_L1", "Locations": "Beijing (China)", "NCTID": "NCT04040699", "Note": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Include": "true"}, {"Gene": "ERBB2", "Alteration": "amplification", "Title": "The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs", "StudyPhase": "PHASE 2", "Target": "BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6", "Locations": "Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)", "NCTID": "NCT05159245", "Note": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Include": "true"}, {"Gene": "ERBB2", "Alteration": "amplification", "Title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "StudyPhase": "PHASE 2", "Target": "ALK, ROS1, AXL, TRKA, MET, TRKC, CDK4, CDK6, FLT3, VEGFRs, CSF1R, KIT, RET, mTOR, ERBB2, MEK, BRAF, PARP, PD_1, CTLA_4, EGFR, ERBB4", "Locations": "Hawaii, Washington, Oregon, California", "NCTID": "NCT02693535", "Note": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Include": "true"}, {"Gene": "ERBB2", "Alteration": "amplification", "Title": "Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985", "StudyPhase": "PHASE 1/2", "Target": "ERBB2", "Locations": "Antwerp (Belgium), Leuven (Belgium), Lille (France), Paris (France), Bordeaux (France), Barcelona (Spain), L Hospitalet De Llobregat (Spain), Lleida (Spain), Madrid (Spain)", "NCTID": "NCT04983238", "Note": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Include": "true"}, {"Gene": "ERBB2", "Alteration": "amplification", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "10679188", "FullCitation": "Biochem. Biophys. Res. Commun. (2000) pmid: 10679188", "Include": "true"}, {"number": "1", "ReferenceId": "23258168", "FullCitation": "Anastas JN, et al. Nat. Rev. Cancer (2013) pmid: 23258168", "Include": "true"}, {"number": "2", "ReferenceId": "9721853", "FullCitation": "Fukuchi T, et al. Cancer Res. (1998) pmid: 9721853", "Include": "true"}, {"number": "3", "ReferenceId": "12824913", "FullCitation": "Cancer Sci. (2003) pmid: 12824913", "Include": "true"}, {"number": "4", "ReferenceId": "16523258", "FullCitation": "Takahashi Y, et al. Virchows Arch. (2006) pmid: 16523258", "Include": "true"}, {"number": "5", "ReferenceId": "11731417", "FullCitation": "Tanaka Y, et al. Cancer Res. (2001) pmid: 11731417", "Include": "true"}, {"number": "6", "ReferenceId": "11943721", "FullCitation": "Abraham SC, et al. Am. J. Pathol. (2002) pmid: 11943721", "Include": "true"}, {"number": "7", "ReferenceId": "18282277", "FullCitation": "Austinat M, et al. Mol. Cancer (2008) pmid: 18282277", "Include": "true"}, {"number": "8", "ReferenceId": "12820959", "FullCitation": "Wu G, et al. Mol. Cell (2003) pmid: 12820959", "Include": "true"}, {"number": "9", "ReferenceId": "15829978", "FullCitation": "Provost E, et al. Oncogene (2005) pmid: 15829978", "Include": "true"}, {"number": "10", "ReferenceId": "10072352", "FullCitation": "Curr. Opin. Genet. Dev. (1999) pmid: 10072352", "Include": "true"}, {"number": "11", "ReferenceId": "17143297", "FullCitation": "Segditsas S, et al. Oncogene (2006) pmid: 17143297", "Include": "true"}, {"number": "12", "ReferenceId": "9024698", "FullCitation": "Barth AI, et al. J. Cell Biol. (1997) pmid: 9024698", "Include": "true"}, {"number": "13", "ReferenceId": "10545105", "FullCitation": "Harada N, et al. EMBO J. (1999) pmid: 10545105", "Include": "true"}, {"number": "14", "ReferenceId": "9671490", "FullCitation": "Hsu SC, et al. Mol. Cell. Biol. (1998) pmid: 9671490", "Include": "true"}, {"number": "15", "ReferenceId": "18491352", "FullCitation": "Breuhahn K, et al. J. Pathol. (2008) pmid: 18491352", "Include": "true"}, {"number": "16", "ReferenceId": "18515740", "FullCitation": "Soon PS, et al. Oncologist (2008) pmid: 18515740", "Include": "true"}, {"number": "17", "ReferenceId": "21212436", "FullCitation": "Tacon LJ, et al. Oncologist (2011) pmid: 21212436", "Include": "true"}, {"number": "18", "ReferenceId": "22266195", "FullCitation": "Simon DP, et al. Mol. Cell. Endocrinol. (2012) pmid: 22266195", "Include": "true"}, {"number": "19", "ReferenceId": "26850916", "FullCitation": "Hirotsu Y, et al. Hepatol. Res. (2016) pmid: 26850916", "Include": "true"}, {"number": "20", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "21", "ReferenceId": "16843618", "FullCitation": "Nozawa N, et al. Pathol. Res. Pract. (2006) pmid: 16843618", "Include": "true"}, {"number": "22", "ReferenceId": "22402266", "FullCitation": "Chiu CG, et al. Am. J. Surg. (2012) pmid: 22402266", "Include": "true"}, {"number": "23", "ReferenceId": "23483484", "FullCitation": "Kim H, et al. Korean J Pathol (2013) pmid: 23483484", "Include": "true"}, {"number": "24", "ReferenceId": "19820688", "FullCitation": "Rosen DG, et al. Mod. Pathol. (2010) pmid: 19820688", "Include": "true"}, {"number": "25", "ReferenceId": "17504383", "FullCitation": "Athanassiadou P, et al. Int. J. Gynecol. Cancer () pmid: 17504383", "Include": "true"}, {"number": "26", "ReferenceId": "30635339", "FullCitation": "Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339", "Include": "true"}, {"number": "27", "ReferenceId": "19403928", "FullCitation": "Tanwar PS, et al. Biol. Reprod. (2009) pmid: 19403928", "Include": "true"}, {"number": "28", "ReferenceId": "21695255", "FullCitation": "Tanwar PS, et al. PLoS ONE (2011) pmid: 21695255", "Include": "true"}, {"number": "29", "ReferenceId": "18768809", "FullCitation": "Fujishita T, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18768809", "Include": "true"}, {"number": "30", "ReferenceId": "20347502", "FullCitation": "Bhoori S, et al. J. Hepatol. (2010) pmid: 20347502", "Include": "true"}, {"number": "31", "ReferenceId": "24931142", "FullCitation": "Janku F, et al. Oncotarget (2014) pmid: 24931142", "Include": "true"}, {"number": "32", "ReferenceId": "25624430", "FullCitation": "Slomovitz BM, et al. J. Clin. Oncol. (2015) pmid: 25624430", "Include": "true"}, {"number": "33", "ReferenceId": "15378020", "FullCitation": "Niida A, et al. Oncogene (2004) pmid: 15378020", "Include": "true"}, {"number": "34", "ReferenceId": "15592430", "FullCitation": "Chamorro MN, et al. EMBO J. (2005) pmid: 15592430", "Include": "true"}, {"number": "35", "ReferenceId": "28574171", "FullCitation": "Kagey MH, et al. Br. J. Pharmacol. (2017) pmid: 28574171", "Include": "true"}, {"number": "36", "ReferenceId": "21841793", "FullCitation": "Kwon C, et al. Nat. Cell Biol. (2011) pmid: 21841793", "Include": "true"}, {"number": "37", "ReferenceId": "23868008", "FullCitation": "Arcaroli JJ, et al. Br. J. Cancer (2013) pmid: 23868008", "Include": "true"}, {"number": "38", "ReferenceId": "26349011", "FullCitation": "Shang H, et al. Cancer (2015) pmid: 26349011", "Include": "true"}, {"number": "39", "ReferenceId": "24429522", "FullCitation": "Kode A, et al. Nature (2014) pmid: 24429522", "Include": "true"}, {"number": "40", "ReferenceId": "25231399", "FullCitation": "Messersmith WA, et al. Clin. Cancer Res. (2015) pmid: 25231399", "Include": "true"}, {"number": "41", "ReferenceId": "22964660", "FullCitation": "Zhu J, et al. Carcinogenesis (2012) pmid: 22964660", "Include": "true"}, {"number": "42", "ReferenceId": "22356261", "FullCitation": "Kogan Y, et al. Biochem. J. (2012) pmid: 22356261", "Include": "true"}, {"number": "43", "ReferenceId": "22811581", "FullCitation": "Lachenmayer A, et al. Clin. Cancer Res. (2012) pmid: 22811581", "Include": "true"}, {"number": "44", "ReferenceId": "21965336", "FullCitation": "Higgins MJ, et al. J. Clin. Invest. (2011) pmid: 21965336", "Include": "true"}, {"number": "45", "ReferenceId": "25480824", "FullCitation": "Chmielecki J, et al. Oncologist (2015) pmid: 25480824", "Include": "true"}, {"number": "46", "ReferenceId": "23000897", "FullCitation": "Nature (2012) pmid: 23000897", "Include": "true"}, {"number": "47", "ReferenceId": "26451490", "FullCitation": "Ciriello G, et al. Cell (2015) pmid: 26451490", "Include": "true"}, {"number": "48", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "49", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "50", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "51", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "52", "ReferenceId": "22461643", "FullCitation": "Sci Transl Med (2012) pmid: 22461643", "Include": "true"}, {"number": "53", "ReferenceId": "19959074", "FullCitation": "Jones KL, et al. Lancet Oncol. (2009) pmid: 19959074", "Include": "true"}, {"number": "54", "ReferenceId": "23749902", "FullCitation": "Rami\u0107 S, et al. Anticancer Res. (2013) pmid: 23749902", "Include": "true"}, {"number": "55", "ReferenceId": "10340889", "FullCitation": "Polkowski W, et al. Ann. Surg. Oncol. () pmid: 10340889", "Include": "true"}, {"number": "56", "ReferenceId": "21359545", "FullCitation": "Haas M, et al. Virchows Arch. (2011) pmid: 21359545", "Include": "true"}, {"number": "57", "ReferenceId": "21783379", "FullCitation": "Maresch J, et al. Crit. Rev. Oncol. Hematol. (2012) pmid: 21783379", "Include": "true"}, {"number": "58", "ReferenceId": "22991510", "FullCitation": "Tsai YS, et al. Adv Urol (2012) pmid: 22991510", "Include": "true"}, {"number": "59", "ReferenceId": "23348520", "FullCitation": "Martin V, et al. Br. J. Cancer (2013) pmid: 23348520", "Include": "true"}, {"number": "60", "ReferenceId": "24879338", "FullCitation": "Seo AN, et al. PLoS ONE (2014) pmid: 24879338", "Include": "true"}, {"number": "61", "ReferenceId": "24146218", "FullCitation": "Sclafani F, et al. Ann. Oncol. (2013) pmid: 24146218", "Include": "true"}, {"number": "62", "ReferenceId": "22374460", "FullCitation": "Harder J, et al. Br. J. Cancer (2012) pmid: 22374460", "Include": "true"}, {"number": "63", "ReferenceId": "19432892", "FullCitation": "Komoto M, et al. Cancer Sci. (2009) pmid: 19432892", "Include": "true"}, {"number": "64", "ReferenceId": "11586103", "FullCitation": "Safran H, et al. Am. J. Clin. Oncol. (2001) pmid: 11586103", "Include": "true"}, {"number": "65", "ReferenceId": "16685109", "FullCitation": "Tsiambas E, et al. JOP (2006) pmid: 16685109", "Include": "true"}, {"number": "66", "ReferenceId": "18463983", "FullCitation": "Sharif S, et al. Dig. Dis. Sci. (2008) pmid: 18463983", "Include": "true"}, {"number": "67", "ReferenceId": "14752523", "FullCitation": "Peir\u00f3 G, et al. Mod. Pathol. (2004) pmid: 14752523", "Include": "true"}, {"number": "68", "ReferenceId": "7585656", "FullCitation": "Saffari B, et al. Cancer Res. (1995) pmid: 7585656", "Include": "true"}, {"number": "69", "ReferenceId": "22611955", "FullCitation": "Kudela M, et al. Eur. J. Gynaecol. Oncol. (2012) pmid: 22611955", "Include": "true"}, {"number": "70", "ReferenceId": "22340411", "FullCitation": "Zhang YF, et al. Chin. Med. J. (2011) pmid: 22340411", "Include": "true"}, {"number": "71", "ReferenceId": "20179235", "FullCitation": "Minner S, et al. Clin. Cancer Res. (2010) pmid: 20179235", "Include": "true"}, {"number": "72", "ReferenceId": "11248153", "FullCitation": "Slamon DJ, et al. N. Engl. J. Med. (2001) pmid: 11248153", "Include": "true"}, {"number": "73", "ReferenceId": "20728210", "FullCitation": "Bang YJ, et al. Lancet (2010) pmid: 20728210", "Include": "true"}, {"number": "74", "ReferenceId": "26358791", "FullCitation": "Chumsri S, et al. J Natl Compr Canc Netw (2015) pmid: 26358791", "Include": "true"}, {"number": "75", "ReferenceId": "16775247", "FullCitation": "Cappuzzo F, et al. N. Engl. J. Med. (2006) pmid: 16775247", "Include": "true"}, {"number": "76", "ReferenceId": "23328556", "FullCitation": "Falchook GS, et al. J Thorac Oncol (2013) pmid: 23328556", "Include": "true"}, {"number": "77", "ReferenceId": "23610105", "FullCitation": "Mazi\u00e8res J, et al. J. Clin. Oncol. (2013) pmid: 23610105", "Include": "true"}, {"number": "78", "ReferenceId": "22149875", "FullCitation": "Baselga J, et al. N. Engl. J. Med. (2012) pmid: 22149875", "Include": "true"}, {"number": "79", "ReferenceId": "25693012", "FullCitation": "Swain SM, et al. N. Engl. J. Med. (2015) pmid: 25693012", "Include": "true"}, {"number": "80", "ReferenceId": "30857956", "FullCitation": "Meric_Bernstam F, et al. Lancet Oncol. (2019) pmid: 30857956", "Include": "true"}, {"number": "81", "ReferenceId": "23020162", "FullCitation": "Verma S, et al. N. Engl. J. Med. (2012) pmid: 23020162", "Include": "true"}, {"number": "82", "ReferenceId": "31825192", "FullCitation": "Modi S, et al. N. Engl. J. Med. (2019) pmid: 31825192", "Include": "true"}, {"number": "83", "ReferenceId": "32469182", "FullCitation": "Shitara K, et al. N. Engl. J. Med. (2020) pmid: 32469182", "Include": "true"}, {"number": "84", "ReferenceId": "34534430", "FullCitation": "Li BT, et al. N Engl J Med (2021) pmid: 34534430", "Include": "true"}, {"number": "85", "ReferenceId": "31825569", "FullCitation": "Murthy RK, et al. N. Engl. J. Med. (2020) pmid: 31825569", "Include": "true"}, {"number": "86", "ReferenceId": "29955792", "FullCitation": "Borges VF, et al. JAMA Oncol (2018) pmid: 29955792", "Include": "true"}, {"number": "87", "ReferenceId": "29804905", "FullCitation": "Murthy R, et al. Lancet Oncol. (2018) pmid: 29804905", "Include": "true"}, {"number": "88", "ReferenceId": "28053022", "FullCitation": "Moulder SL, et al. Clin. Cancer Res. (2017) pmid: 28053022", "Include": "true"}, {"number": "89", "ReferenceId": "32478891", "FullCitation": "Fan Y, et al. Mol Oncol (2020) pmid: 32478891", "Include": "true"}, {"number": "90", "ReferenceId": "20736298", "FullCitation": "Cameron D, et al. Oncologist (2010) pmid: 20736298", "Include": "true"}, {"number": "91", "ReferenceId": "17192538", "FullCitation": "Geyer CE, et al. N. Engl. J. Med. (2006) pmid: 17192538", "Include": "true"}, {"number": "92", "ReferenceId": "23950206", "FullCitation": "Serra V, et al. Cancer Discov (2013) pmid: 23950206", "Include": "true"}, {"number": "93", "ReferenceId": "24516025", "FullCitation": "Ali SM, et al. J. Clin. Oncol. (2014) pmid: 24516025", "Include": "true"}, {"number": "94", "ReferenceId": "26487584", "FullCitation": "Grellety T, et al. Ann. Oncol. (2016) pmid: 26487584", "Include": "true"}, {"number": "95", "ReferenceId": "25085898", "FullCitation": "Vornicova O, et al. Oncologist (2014) pmid: 25085898", "Include": "true"}, {"number": "96", "ReferenceId": "32017710", "FullCitation": "Ronellenfitsch MW, et al. J Clin Invest (2020) pmid: 32017710", "Include": "true"}, {"number": "97", "ReferenceId": "32405522", "FullCitation": "Hou JY, et al. Gynecol Oncol Rep (2020) pmid: 32405522", "Include": "true"}, {"number": "98", "ReferenceId": "22418700", "FullCitation": "Lin NU, et al. Breast Cancer Res. Treat. (2012) pmid: 22418700", "Include": "true"}, {"number": "99", "ReferenceId": "25268372", "FullCitation": "Schwab CL, et al. Br. J. Cancer (2014) pmid: 25268372", "Include": "true"}, {"number": "100", "ReferenceId": "25682316", "FullCitation": "De Gr\u00e8ve J, et al. Lung Cancer (2015) pmid: 25682316", "Include": "true"}, {"number": "101", "ReferenceId": "22325357", "FullCitation": "De Gr\u00e8ve J, et al. Lung Cancer (2012) pmid: 22325357", "Include": "true"}, {"number": "102", "ReferenceId": "26559459", "FullCitation": "Li BT, et al. Lung Cancer (2015) pmid: 26559459", "Include": "true"}, {"number": "103", "ReferenceId": "30825613", "FullCitation": "Dziadziuszko R, et al. J Thorac Oncol (2019) pmid: 30825613", "Include": "true"}, {"number": "104", "ReferenceId": "30685684", "FullCitation": "Lai WV, et al. Eur. J. Cancer (2019) pmid: 30685684", "Include": "true"}, {"number": "105", "ReferenceId": "30425522", "FullCitation": "Liu Z, et al. Onco Targets Ther (2018) pmid: 30425522", "Include": "true"}, {"number": "106", "ReferenceId": "31748336", "FullCitation": "Fang W, et al. Oncologist (2019) pmid: 31748336", "Include": "true"}, {"number": "107", "ReferenceId": "32477948", "FullCitation": "Yuan B, et al. Front Oncol (2020) pmid: 32477948", "Include": "true"}, {"number": "108", "ReferenceId": "26358790", "FullCitation": "Ben_Baruch NE, et al. J Natl Compr Canc Netw (2015) pmid: 26358790", "Include": "true"}, {"number": "109", "ReferenceId": "28679771", "FullCitation": "Ma CX, et al. Clin. Cancer Res. (2017) pmid: 28679771", "Include": "true"}, {"number": "110", "ReferenceId": "29420467", "FullCitation": "Hyman DM, et al. Nature (2018) pmid: 29420467", "Include": "true"}, {"number": "111", "ReferenceId": "31806627", "FullCitation": "Smyth LM, et al. Cancer Discov (2019) pmid: 31806627", "Include": "true"}, {"number": "112", "ReferenceId": "25899785", "FullCitation": "Kris MG, et al. Ann. Oncol. (2015) pmid: 25899785", "Include": "true"}, {"number": "113", "ReferenceId": "30596880", "FullCitation": "Wang Y, et al. Ann. Oncol. (2019) pmid: 30596880", "Include": "true"}, {"number": "114", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "115", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "116", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "117", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "118", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "119", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "120", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "121", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "122", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "123", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "124", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "125", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "126", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "127", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "128", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "129", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "130", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "131", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "132", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "133", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "134", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "135", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "136", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "137", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "138", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "139", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "140", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "141", "ReferenceId": "15918185", "FullCitation": "Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185", "Include": "true"}, {"number": "142", "ReferenceId": "14656944", "FullCitation": "Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944", "Include": "true"}, {"number": "143", "ReferenceId": "11223838", "FullCitation": "Suto T, et al. J Surg Oncol (2001) pmid: 11223838", "Include": "true"}, {"number": "144", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "145", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "146", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "147", "ReferenceId": "11063221", "FullCitation": "Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221", "Include": "true"}, {"number": "148", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "149", "ReferenceId": "17233803", "FullCitation": "Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803", "Include": "true"}, {"number": "150", "ReferenceId": "16924473", "FullCitation": "Burger M, et al. J. Mol. Med. (2006) pmid: 16924473", "Include": "true"}, {"number": "151", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "152", "ReferenceId": "25319978", "FullCitation": "Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978", "Include": "true"}, {"number": "153", "ReferenceId": "16675567", "FullCitation": "Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567", "Include": "true"}, {"number": "154", "ReferenceId": "25026289", "FullCitation": "Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289", "Include": "true"}, {"number": "155", "ReferenceId": "20304627", "FullCitation": "Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627", "Include": "true"}, {"number": "156", "ReferenceId": "19275958", "FullCitation": "Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958", "Include": "true"}, {"number": "157", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "158", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "159", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "160", "ReferenceId": "24263190", "FullCitation": "Goel HL, et al. Nat. Rev. Cancer (2013) pmid: 24263190", "Include": "true"}, {"number": "161", "ReferenceId": "24687604", "FullCitation": "Horwitz E, et al. Cancer Discov (2014) pmid: 24687604", "Include": "true"}, {"number": "162", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "163", "ReferenceId": "21743435", "FullCitation": "Vlajnic T, et al. Mod. Pathol. (2011) pmid: 21743435", "Include": "true"}, {"number": "164", "ReferenceId": "24807156", "FullCitation": "Mok T, et al. J Thorac Oncol (2014) pmid: 24807156", "Include": "true"}, {"number": "165", "ReferenceId": "23169435", "FullCitation": "Hegde PS, et al. Clin. Cancer Res. (2013) pmid: 23169435", "Include": "true"}, {"number": "166", "ReferenceId": "25374209", "FullCitation": "Du K, et al. Asian Pac. J. Cancer Prev. (2014) pmid: 25374209", "Include": "true"}, {"number": "167", "ReferenceId": "25158264", "FullCitation": "Hong YM, et al. Genet. Mol. Res. (2014) pmid: 25158264", "Include": "true"}, {"number": "168", "ReferenceId": "22565005", "FullCitation": "Van Cutsem E, et al. J. Clin. Oncol. (2012) pmid: 22565005", "Include": "true"}, {"number": "169", "ReferenceId": "24370903", "FullCitation": "Park DJ, et al. Ann. Surg. Oncol. (2014) pmid: 24370903", "Include": "true"}, {"number": "170", "ReferenceId": "18665074", "FullCitation": "Chang YT, et al. Pancreas (2008) pmid: 18665074", "Include": "true"}, {"number": "171", "ReferenceId": "24480377", "FullCitation": "Georgiadou D, et al. Eur J Surg Oncol (2014) pmid: 24480377", "Include": "true"}, {"number": "172", "ReferenceId": "21729304", "FullCitation": "Rahbari NN, et al. BMC Cancer (2011) pmid: 21729304", "Include": "true"}, {"number": "173", "ReferenceId": "23422754", "FullCitation": "Miles DW, et al. Br. J. Cancer (2013) pmid: 23422754", "Include": "true"}, {"number": "174", "ReferenceId": "23569311", "FullCitation": "Gianni L, et al. J. Clin. Oncol. (2013) pmid: 23569311", "Include": "true"}, {"number": "175", "ReferenceId": "23932548", "FullCitation": "Cameron D, et al. Lancet Oncol. (2013) pmid: 23932548", "Include": "true"}, {"number": "176", "ReferenceId": "23340303", "FullCitation": "Schneider BP, et al. Clin. Cancer Res. (2013) pmid: 23340303", "Include": "true"}, {"number": "177", "ReferenceId": "26627848", "FullCitation": "Baumgarten P, et al. Neuro_oncology (2016) pmid: 26627848", "Include": "true"}, {"number": "178", "ReferenceId": "18182667", "FullCitation": "Sathornsumetee S, et al. J. Clin. Oncol. (2008) pmid: 18182667", "Include": "true"}, {"number": "179", "ReferenceId": "31582283", "FullCitation": "Olafson LR, et al. J Clin Neurosci (2019) pmid: 31582283", "Include": "true"}, {"number": "180", "ReferenceId": "20484123", "FullCitation": "Duda DG, et al. Oncologist (2010) pmid: 20484123", "Include": "true"}, {"number": "181", "ReferenceId": "27535973", "FullCitation": "Stremitzer S, et al. Mol. Cancer Ther. (2016) pmid: 27535973", "Include": "true"}, {"number": "182", "ReferenceId": "26125443", "FullCitation": "Weickhardt AJ, et al. Br. J. Cancer (2015) pmid: 26125443", "Include": "true"}, {"number": "183", "ReferenceId": "20008624", "FullCitation": "Kopetz S, et al. J. Clin. Oncol. (2010) pmid: 20008624", "Include": "true"}, {"number": "184", "ReferenceId": "21868552", "FullCitation": "Fountzilas G, et al. Anticancer Res. (2011) pmid: 21868552", "Include": "true"}, {"number": "185", "ReferenceId": "23397155", "FullCitation": "S\u00e1nchez_Rovira P, et al. Clin Transl Oncol (2013) pmid: 23397155", "Include": "true"}, {"number": "186", "ReferenceId": "24577128", "FullCitation": "An SJ, et al. Cancer Gene Ther. (2014) pmid: 24577128", "Include": "true"}, {"number": "187", "ReferenceId": "29059426", "FullCitation": "Bais C, et al. J. Natl. Cancer Inst. (2017) pmid: 29059426", "Include": "true"}, {"number": "188", "ReferenceId": "19826039", "FullCitation": "Xu L, et al. Cancer Res. (2009) pmid: 19826039", "Include": "true"}, {"number": "189", "ReferenceId": "20666740", "FullCitation": "Hasselbalch B, et al. APMIS (2010) pmid: 20666740", "Include": "true"}, {"number": "190", "ReferenceId": "28465540", "FullCitation": "Marisi G, et al. Sci Rep (2017) pmid: 28465540", "Include": "true"}, {"number": "191", "ReferenceId": "16365183", "FullCitation": "Jubb AM, et al. J. Clin. Oncol. (2006) pmid: 16365183", "Include": "true"}, {"number": "192", "ReferenceId": "20924372", "FullCitation": "Goede V, et al. Br. J. Cancer (2010) pmid: 20924372", "Include": "true"}, {"number": "193", "ReferenceId": "24374727", "FullCitation": "Bruhn MA, et al. Int. J. Cancer (2014) pmid: 24374727", "Include": "true"}, {"number": "194", "ReferenceId": "18156031", "FullCitation": "Escudier B, et al. Lancet (2007) pmid: 18156031", "Include": "true"}, {"number": "195", "ReferenceId": "12890841", "FullCitation": "Yang JC, et al. N. Engl. J. Med. (2003) pmid: 12890841", "Include": "true"}, {"number": "196", "ReferenceId": "19047116", "FullCitation": "Burstein HJ, et al. Clin. Cancer Res. (2008) pmid: 19047116", "Include": "true"}, {"number": "197", "ReferenceId": "21224365", "FullCitation": "Jubb AM, et al. Clin. Cancer Res. (2011) pmid: 21224365", "Include": "true"}, {"number": "198", "ReferenceId": "27817944", "FullCitation": "Miles D, et al. Eur. J. Cancer (2017) pmid: 27817944", "Include": "true"}, {"number": "199", "ReferenceId": "18316562", "FullCitation": "Dowlati A, et al. Clin. Cancer Res. (2008) pmid: 18316562", "Include": "true"}, {"number": "200", "ReferenceId": "19826110", "FullCitation": "Horn L, et al. J. Clin. Oncol. (2009) pmid: 19826110", "Include": "true"}, {"number": "201", "ReferenceId": "26976425", "FullCitation": "Blakeley JO, et al. J. Clin. Oncol. (2016) pmid: 26976425", "Include": "true"}, {"number": "202", "ReferenceId": "30935424", "FullCitation": "Oh CR, et al. BMC Cancer (2019) pmid: 30935424", "Include": "true"}, {"number": "203", "ReferenceId": "19686080", "FullCitation": "Moldovan GL, et al. Annu. Rev. Genet. (2009) pmid: 19686080", "Include": "true"}, {"number": "204", "ReferenceId": "21568838", "FullCitation": "Deakyne JS, et al. Biochemistry Mosc. (2011) pmid: 21568838", "Include": "true"}, {"number": "205", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "206", "ReferenceId": "24200853", "FullCitation": "Ghosh S, et al. Am. J. Pathol. (2014) pmid: 24200853", "Include": "true"}, {"number": "207", "ReferenceId": "25609062", "FullCitation": "Lombardi AJ, et al. Clin. Cancer Res. (2015) pmid: 25609062", "Include": "true"}, {"number": "208", "ReferenceId": "22522925", "FullCitation": "Curtis C, et al. Nature (2012) pmid: 22522925", "Include": "true"}, {"number": "209", "ReferenceId": "9331070", "FullCitation": "Teng DH, et al. Cancer Res. (1997) pmid: 9331070", "Include": "true"}, {"number": "210", "ReferenceId": "21896780", "FullCitation": "Ahn YH, et al. Mol. Cell. Biol. (2011) pmid: 21896780", "Include": "true"}, {"number": "211", "ReferenceId": "21575258", "FullCitation": "Davis SJ, et al. BMC Cancer (2011) pmid: 21575258", "Include": "true"}, {"number": "212", "ReferenceId": "16115952", "FullCitation": "Lee HY, et al. Clin. Cancer Res. (2005) pmid: 16115952", "Include": "true"}, {"number": "213", "ReferenceId": "12714585", "FullCitation": "Lee HY, et al. J. Biol. Chem. (2003) pmid: 12714585", "Include": "true"}, {"number": "214", "ReferenceId": "16740690", "FullCitation": "Cunningham SC, et al. Cancer Res. (2006) pmid: 16740690", "Include": "true"}, {"number": "215", "ReferenceId": "20668451", "FullCitation": "Kan Z, et al. Nature (2010) pmid: 20668451", "Include": "true"}, {"number": "216", "ReferenceId": "15866172", "FullCitation": "Takekawa M, et al. Mol. Cell (2005) pmid: 15866172", "Include": "true"}, {"number": "217", "ReferenceId": "21372598", "FullCitation": "Ishikawa M, et al. Oncology (2010) pmid: 21372598", "Include": "true"}, {"number": "218", "ReferenceId": "16489030", "FullCitation": "Hickson JA, et al. Cancer Res. (2006) pmid: 16489030", "Include": "true"}, {"number": "219", "ReferenceId": "29795445", "FullCitation": "Xue Z, et al. Cell Res (2018) pmid: 29795445", "Include": "true"}, {"number": "220", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "221", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "222", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "223", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "224", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "225", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "226", "ReferenceId": "24132290", "FullCitation": "Kandoth C, et al. Nature (2013) pmid: 24132290", "Include": "true"}, {"number": "227", "ReferenceId": "16537709", "FullCitation": "Wongsurawat VJ, et al. Cancer Epidemiol. Biomarkers Prev. (2006) pmid: 16537709", "Include": "true"}, {"number": "228", "ReferenceId": "19693097", "FullCitation": "Brosh R, et al. Nat. Rev. Cancer (2009) pmid: 19693097", "Include": "true"}, {"number": "229", "ReferenceId": "2649981", "FullCitation": "Baker SJ, et al. Science (1989) pmid: 2649981", "Include": "true"}, {"number": "230", "ReferenceId": "24053468", "FullCitation": "Calcagno DQ, et al. BMC Gastroenterol (2013) pmid: 24053468", "Include": "true"}, {"number": "231", "ReferenceId": "18465328", "FullCitation": "Alsner J, et al. Acta Oncol (2008) pmid: 18465328", "Include": "true"}, {"number": "232", "ReferenceId": "16489069", "FullCitation": "Olivier M, et al. Clin. Cancer Res. (2006) pmid: 16489069", "Include": "true"}, {"number": "233", "ReferenceId": "23359294", "FullCitation": "V\u00e9gran F, et al. PLoS ONE (2013) pmid: 23359294", "Include": "true"}, {"number": "234", "ReferenceId": "22678923", "FullCitation": "Wild PJ, et al. EMBO Mol Med (2012) pmid: 22678923", "Include": "true"}, {"number": "235", "ReferenceId": "20006376", "FullCitation": "Lee EJ, et al. Gynecol. Oncol. (2010) pmid: 20006376", "Include": "true"}, {"number": "236", "ReferenceId": "24107801", "FullCitation": "Ganci F, et al. Ann. Oncol. (2013) pmid: 24107801", "Include": "true"}, {"number": "237", "ReferenceId": "21467160", "FullCitation": "Lindenbergh_van der Plas M, et al. Clin. Cancer Res. (2011) pmid: 21467160", "Include": "true"}, {"number": "238", "ReferenceId": "21513535", "FullCitation": "Peltonen JK, et al. Head Neck Oncol (2011) pmid: 21513535", "Include": "true"}, {"number": "239", "ReferenceId": "9761125", "FullCitation": "Bringuier PP, et al. Int. J. Cancer (1998) pmid: 9761125", "Include": "true"}, {"number": "240", "ReferenceId": "24500328", "FullCitation": "Feng C, et al. Sci Rep (2014) pmid: 24500328", "Include": "true"}, {"number": "241", "ReferenceId": "28039262", "FullCitation": "Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262", "Include": "true"}, {"number": "242", "ReferenceId": "16172461", "FullCitation": "Russo A, et al. J. Clin. Oncol. (2005) pmid: 16172461", "Include": "true"}, {"number": "243", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "244", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "245", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "246", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "247", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "248", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "249", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "250", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "251", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "252", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "253", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "254", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "255", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "256", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "257", "ReferenceId": "22965953", "FullCitation": "Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953", "Include": "true"}, {"number": "258", "ReferenceId": "26086967", "FullCitation": "Mohell N, et al. Cell Death Dis (2015) pmid: 26086967", "Include": "true"}, {"number": "259", "ReferenceId": "27179933", "FullCitation": "Fransson \u00c5, et al. J Ovarian Res (2016) pmid: 27179933", "Include": "true"}, {"number": "260", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "261", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "262", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "263", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "264", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "265", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "266", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "267", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "268", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "269", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "270", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "271", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "272", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "273", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "274", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "275", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "276", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "277", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "278", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "279", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "280", "ReferenceId": "15220362", "FullCitation": "Morris MR, et al. J. Clin. Pathol. (2004) pmid: 15220362", "Include": "true"}, {"number": "281", "ReferenceId": "31085323", "FullCitation": "Schmidt C, et al. Semin Cell Dev Biol (2020) pmid: 31085323", "Include": "true"}, {"number": "282", "ReferenceId": "16155190", "FullCitation": "Lehtonen HJ, et al. J Med Genet (2006) pmid: 16155190", "Include": "true"}, {"number": "283", "ReferenceId": "11865300", "FullCitation": "Tomlinson IP, et al. Nat. Genet. (2002) pmid: 11865300", "Include": "true"}, {"number": "284", "ReferenceId": "21398687", "FullCitation": "Gardie B, et al. J Med Genet (2011) pmid: 21398687", "Include": "true"}, {"number": "285", "ReferenceId": "31524643", "FullCitation": "Lau HD, et al. Am J Surg Pathol (2020) pmid: 31524643", "Include": "true"}, {"number": "286", "ReferenceId": "25490448", "FullCitation": "Sourbier C, et al. Cancer Cell (2014) pmid: 25490448", "Include": "true"}, {"number": "287", "ReferenceId": "24334767", "FullCitation": "Castro_Vega LJ, et al. Hum Mol Genet (2014) pmid: 24334767", "Include": "true"}, {"number": "288", "ReferenceId": "28300276", "FullCitation": "Muller M, et al. Clin Genet (2017) pmid: 28300276", "Include": "true"}, {"number": "289", "ReferenceId": "21404119", "FullCitation": "Fam Cancer (2011) pmid: 21404119", "Include": "true"}, {"number": "290", "ReferenceId": "31831373", "FullCitation": "Forde C, et al. Eur Urol Oncol (2019) pmid: 31831373", "Include": "true"}, {"number": "291", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "292", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "293", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "294", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "295", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "296", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "297", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "298", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "299", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "300", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "301", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "302", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "303", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "304", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "305", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "306", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "307", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "308", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "309", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "310", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "311", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "312", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "313", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "314", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "315", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "316", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "317", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "318", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "319", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "320", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "321", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "322", "ReferenceId": "25873077", "FullCitation": "Jafri M, et al. Cancer Discov (2015) pmid: 25873077", "Include": "true"}, {"number": "323", "ReferenceId": "25589618", "FullCitation": "Li YY, et al. Clin. Cancer Res. (2015) pmid: 25589618", "Include": "true"}, {"number": "324", "ReferenceId": "25631445", "FullCitation": "Nature (2015) pmid: 25631445", "Include": "true"}, {"number": "325", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "326", "ReferenceId": "24670651", "FullCitation": "Song Y, et al. Nature (2014) pmid: 24670651", "Include": "true"}, {"number": "327", "ReferenceId": "24686850", "FullCitation": "Lin DC, et al. Nat. Genet. (2014) pmid: 24686850", "Include": "true"}, {"number": "328", "ReferenceId": "23470568", "FullCitation": "Oshima M, et al. Ann. Surg. (2013) pmid: 23470568", "Include": "true"}, {"number": "329", "ReferenceId": "17600882", "FullCitation": "Tsiambas E, et al. J BUON () pmid: 17600882", "Include": "true"}, {"number": "330", "ReferenceId": "23254264", "FullCitation": "Yanagawa N, et al. Lung Cancer (2013) pmid: 23254264", "Include": "true"}, {"number": "331", "ReferenceId": "20665497", "FullCitation": "Chang DT, et al. Cancer (2010) pmid: 20665497", "Include": "true"}, {"number": "332", "ReferenceId": "12060614", "FullCitation": "Lee TL, et al. Clin. Cancer Res. (2002) pmid: 12060614", "Include": "true"}, {"number": "333", "ReferenceId": "21302620", "FullCitation": "Hu SL, et al. Tumori () pmid: 21302620", "Include": "true"}, {"number": "334", "ReferenceId": "22206050", "FullCitation": "Shi J, et al. Am J Cancer Res (2012) pmid: 22206050", "Include": "true"}, {"number": "335", "ReferenceId": "23111194", "FullCitation": "Bradly DP, et al. Diagn. Mol. Pathol. (2012) pmid: 23111194", "Include": "true"}, {"number": "336", "ReferenceId": "23372805", "FullCitation": "Lou_Qian Z, et al. PLoS ONE (2013) pmid: 23372805", "Include": "true"}, {"number": "337", "ReferenceId": "23614702", "FullCitation": "Tan S, et al. Exp. Lung Res. () pmid: 23614702", "Include": "true"}, {"number": "338", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "339", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "340", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "341", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "342", "ReferenceId": "35157829", "FullCitation": "Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829", "Include": "true"}, {"number": "343", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "344", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "345", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "346", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "347", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "348", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "349", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "350", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "351", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "352", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "353", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "354", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "355", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "356", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "357", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "358", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "359", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "360", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "361", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "362", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "363", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "364", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "365", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "366", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "367", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "368", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "369", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "370", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "371", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "372", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "373", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "374", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "375", "ReferenceId": "27022117", "FullCitation": "Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117", "Include": "true"}, {"number": "376", "ReferenceId": "27009843", "FullCitation": "Xiao D, et al. Oncotarget (2016) pmid: 27009843", "Include": "true"}, {"number": "377", "ReferenceId": "26200269", "FullCitation": "Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269", "Include": "true"}, {"number": "378", "ReferenceId": "22980976", "FullCitation": "Govindan R, et al. Cell (2012) pmid: 22980976", "Include": "true"}, {"number": "379", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "380", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "381", "ReferenceId": "24323028", "FullCitation": "Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028", "Include": "true"}, {"number": "382", "ReferenceId": "11535541", "FullCitation": "Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541", "Include": "true"}, {"number": "383", "ReferenceId": "12445368", "FullCitation": "Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368", "Include": "true"}, {"number": "384", "ReferenceId": "12820457", "FullCitation": "Brueckl WM, et al. Anticancer Res. () pmid: 12820457", "Include": "true"}, {"number": "385", "ReferenceId": "11438476", "FullCitation": "Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476", "Include": "true"}, {"number": "386", "ReferenceId": "10631274", "FullCitation": "Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274", "Include": "true"}, {"number": "387", "ReferenceId": "16952542", "FullCitation": "Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542", "Include": "true"}, {"number": "388", "ReferenceId": "22722556", "FullCitation": "Laghi L, et al. Dig Dis (2012) pmid: 22722556", "Include": "true"}, {"number": "389", "ReferenceId": "27159395", "FullCitation": "Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395", "Include": "true"}, {"number": "390", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "391", "ReferenceId": "23528559", "FullCitation": "Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559", "Include": "true"}, {"number": "392", "ReferenceId": "24777035", "FullCitation": "Cazier JB, et al. Nat Commun (2014) pmid: 24777035", "Include": "true"}, {"number": "393", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "394", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "395", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "396", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "397", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "398", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "399", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "400", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "401", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "402", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "403", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "404", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "405", "ReferenceId": "2986437", "FullCitation": "Opsomer RJ, et al. Acta Urol Belg (1985) pmid: 2986437", "Include": "true"}, {"number": "406", "ReferenceId": "28958502", "FullCitation": "Wu YL, et al. Lancet Oncol. (2017) pmid: 28958502", "Include": "true"}, {"number": "407", "ReferenceId": "28921872", "FullCitation": "Necchi A, et al. BJU Int. (2018) pmid: 28921872", "Include": "true"}, {"number": "408", "ReferenceId": "25424851", "FullCitation": "Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851", "Include": "true"}, {"number": "409", "ReferenceId": "26462025", "FullCitation": "Kim HS, et al. Oncotarget (2015) pmid: 26462025", "Include": "true"}, {"number": "410", "ReferenceId": "29734047", "FullCitation": "Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047", "Include": "true"}, {"number": "411", "ReferenceId": "26581547", "FullCitation": "Oh DY, et al. Gastric Cancer (2016) pmid: 26581547", "Include": "true"}, {"number": "412", "ReferenceId": "28575464", "FullCitation": "Sep\u00falveda_S\u00e1nchez JM, et al. Neuro_oncology (2017) pmid: 28575464", "Include": "true"}, {"number": "413", "ReferenceId": "21220471", "FullCitation": "J\u00e4nne PA, et al. Clin. Cancer Res. (2011) pmid: 21220471", "Include": "true"}, {"number": "414", "ReferenceId": "24501009", "FullCitation": "Reckamp KL, et al. Cancer (2014) pmid: 24501009", "Include": "true"}, {"number": "415", "ReferenceId": "28119295", "FullCitation": "Bang YJ, et al. Ann. Oncol. (2017) pmid: 28119295", "Include": "true"}, {"number": "416", "ReferenceId": "32213540", "FullCitation": "Tsurutani J, et al. Cancer Discov (2020) pmid: 32213540", "Include": "true"}, {"number": "417", "ReferenceId": "31047803", "FullCitation": "Tamura K, et al. Lancet Oncol. (2019) pmid: 31047803", "Include": "true"}, {"number": "418", "ReferenceId": "31047804", "FullCitation": "Shitara K, et al. Lancet Oncol. (2019) pmid: 31047804", "Include": "true"}, {"number": "419", "ReferenceId": "24793816", "FullCitation": "Krop IE, et al. Lancet Oncol. (2014) pmid: 24793816", "Include": "true"}, {"number": "420", "ReferenceId": "24222194", "FullCitation": "Welslau M, et al. Cancer (2014) pmid: 24222194", "Include": "true"}, {"number": "421", "ReferenceId": "22649126", "FullCitation": "Krop IE, et al. J. Clin. Oncol. (2012) pmid: 22649126", "Include": "true"}, {"number": "422", "ReferenceId": "21172893", "FullCitation": "Burris HA, et al. J. Clin. Oncol. (2011) pmid: 21172893", "Include": "true"}, {"number": "423", "ReferenceId": "31504139", "FullCitation": "Jhaveri KL, et al. Ann. Oncol. (2019) pmid: 31504139", "Include": "true"}, {"number": "424", "ReferenceId": "32213539", "FullCitation": "Li BT, et al. Cancer Discov (2020) pmid: 32213539", "Include": "true"}, {"number": "425", "ReferenceId": "29313813", "FullCitation": "Hotta K, et al. J Thorac Oncol (2018) pmid: 29313813", "Include": "true"}, {"number": "426", "ReferenceId": "26920887", "FullCitation": "Baselga J, et al. Clin. Cancer Res. (2016) pmid: 26920887", "Include": "true"}, {"number": "427", "ReferenceId": "28056202", "FullCitation": "Perez EA, et al. J. Clin. Oncol. (2017) pmid: 28056202", "Include": "true"}, {"number": "428", "ReferenceId": "23382472", "FullCitation": "Hurvitz SA, et al. J. Clin. Oncol. (2013) pmid: 23382472", "Include": "true"}, {"number": "429", "ReferenceId": "30516102", "FullCitation": "von Minckwitz G, et al. N. Engl. J. Med. (2019) pmid: 30516102", "Include": "true"}, {"number": "430", "ReferenceId": "31157583", "FullCitation": "Hurvitz SA, et al. J. Clin. Oncol. (2019) pmid: 31157583", "Include": "true"}, {"number": "431", "ReferenceId": "27052654", "FullCitation": "Martin M, et al. Ann. Oncol. (2016) pmid: 27052654", "Include": "true"}, {"number": "432", "ReferenceId": "32923849", "FullCitation": "Mondaca S, et al. JCO Precis Oncol (2019) pmid: 32923849", "Include": "true"}, {"number": "433", "ReferenceId": "20142587", "FullCitation": "Burstein HJ, et al. J. Clin. Oncol. (2010) pmid: 20142587", "Include": "true"}, {"number": "434", "ReferenceId": "26834058", "FullCitation": "Freedman RA, et al. J. Clin. Oncol. (2016) pmid: 26834058", "Include": "true"}, {"number": "435", "ReferenceId": "26874901", "FullCitation": "Chan A, et al. Lancet Oncol. (2016) pmid: 26874901", "Include": "true"}, {"number": "436", "ReferenceId": "25287822", "FullCitation": "Saura C, et al. J. Clin. Oncol. (2014) pmid: 25287822", "Include": "true"}, {"number": "437", "ReferenceId": "22967996", "FullCitation": "Awada A, et al. Ann. Oncol. (2013) pmid: 22967996", "Include": "true"}, {"number": "438", "ReferenceId": "23953056", "FullCitation": "Martin M, et al. Eur. J. Cancer (2013) pmid: 23953056", "Include": "true"}, {"number": "439", "ReferenceId": "23632474", "FullCitation": "Chow LW, et al. Br. J. Cancer (2013) pmid: 23632474", "Include": "true"}, {"number": "440", "ReferenceId": "27406346", "FullCitation": "Park JW, et al. N. Engl. J. Med. (2016) pmid: 27406346", "Include": "true"}, {"number": "441", "ReferenceId": "27078022", "FullCitation": "Awada A, et al. JAMA Oncol (2016) pmid: 27078022", "Include": "true"}, {"number": "442", "ReferenceId": "24323026", "FullCitation": "Gandhi L, et al. J. Clin. Oncol. (2014) pmid: 24323026", "Include": "true"}, {"number": "443", "ReferenceId": "26260909", "FullCitation": "Schwab CL, et al. Gynecol. Oncol. (2015) pmid: 26260909", "Include": "true"}, {"number": "444", "ReferenceId": "28397106", "FullCitation": "Menderes G, et al. Med. Oncol. (2017) pmid: 28397106", "Include": "true"}, {"number": "445", "ReferenceId": "26375550", "FullCitation": "Hu Z, et al. Oncotarget (2015) pmid: 26375550", "Include": "true"}, {"number": "446", "ReferenceId": "26243863", "FullCitation": "Kavuri SM, et al. Cancer Discov (2015) pmid: 26243863", "Include": "true"}, {"number": "447", "ReferenceId": "23220880", "FullCitation": "Bose R, et al. Cancer Discov (2013) pmid: 23220880", "Include": "true"}, {"number": "448", "ReferenceId": "2932031", "FullCitation": "Hempstead RW, et al. Am J Dermatopathol (1985) pmid: 2932031", "Include": "true"}, {"number": "449", "ReferenceId": "29175149", "FullCitation": "Hurvitz SA, et al. Lancet Oncol. (2018) pmid: 29175149", "Include": "true"}, {"number": "450", "ReferenceId": "28581356", "FullCitation": "von Minckwitz G, et al. N. Engl. J. Med. (2017) pmid: 28581356", "Include": "true"}, {"number": "451", "ReferenceId": "29320312", "FullCitation": "Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312", "Include": "true"}, {"number": "452", "ReferenceId": "29253081", "FullCitation": "Swain SM, et al. Ann Oncol (2018) pmid: 29253081", "Include": "true"}, {"number": "453", "ReferenceId": "27179402", "FullCitation": "Gianni L, et al. Lancet Oncol. (2016) pmid: 27179402", "Include": "true"}, {"number": "454", "ReferenceId": "31647503", "FullCitation": "Shao Z, et al. JAMA Oncol (2020) pmid: 31647503", "Include": "true"}, {"number": "455", "ReferenceId": "23816960", "FullCitation": "Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960", "Include": "true"}, {"number": "456", "ReferenceId": "23816963", "FullCitation": "Katakami N, et al. J. Clin. Oncol. (2013) pmid: 23816963", "Include": "true"}, {"number": "457", "ReferenceId": "20679611", "FullCitation": "Yap TA, et al. J. Clin. Oncol. (2010) pmid: 20679611", "Include": "true"}, {"number": "458", "ReferenceId": "18026190", "FullCitation": "Eskens FA, et al. Br. J. Cancer (2008) pmid: 18026190", "Include": "true"}, {"number": "459", "ReferenceId": "23775486", "FullCitation": "Kwak EL, et al. Cancer (2013) pmid: 23775486", "Include": "true"}, {"number": "460", "ReferenceId": "23414476", "FullCitation": "Marshall J, et al. Future Oncol (2013) pmid: 23414476", "Include": "true"}, {"number": "461", "ReferenceId": "24371631", "FullCitation": "Talwar S, et al. Gynecol Oncol Case Rep (2012) pmid: 24371631", "Include": "true"}, {"number": "462", "ReferenceId": "27044931", "FullCitation": "Choudhury NJ, et al. J. Clin. Oncol. (2016) pmid: 27044931", "Include": "true"}, {"number": "463", "ReferenceId": "25537159", "FullCitation": "Rimawi MF, et al. Clin. Breast Cancer (2015) pmid: 25537159", "Include": "true"}, {"number": "464", "ReferenceId": "26835225", "FullCitation": "Gunzer K, et al. Springerplus (2016) pmid: 26835225", "Include": "true"}, {"number": "465", "ReferenceId": "23578997", "FullCitation": "Janjigian YY, et al. J. Nucl. Med. (2013) pmid: 23578997", "Include": "true"}, {"number": "466", "ReferenceId": "24657003", "FullCitation": "Gianni L, et al. Lancet Oncol. (2014) pmid: 24657003", "Include": "true"}, {"number": "467", "ReferenceId": "24037735", "FullCitation": "Morris PG, et al. Cancer (2013) pmid: 24037735", "Include": "true"}, {"number": "468", "ReferenceId": "25130998", "FullCitation": "de Azambuja E, et al. Lancet Oncol. (2014) pmid: 25130998", "Include": "true"}, {"number": "469", "ReferenceId": "12907212", "FullCitation": "Haddad R, et al. Oral Oncol. (2003) pmid: 12907212", "Include": "true"}, {"number": "470", "ReferenceId": "23429737", "FullCitation": "Limaye SA, et al. Oncologist (2013) pmid: 23429737", "Include": "true"}, {"number": "471", "ReferenceId": "17097832", "FullCitation": "Safran H, et al. Int. J. Radiat. Oncol. Biol. Phys. (2007) pmid: 17097832", "Include": "true"}, {"number": "472", "ReferenceId": "27334835", "FullCitation": "Wang K, et al. Clin. Cancer Res. (2016) pmid: 27334835", "Include": "true"}, {"number": "473", "ReferenceId": "27521503", "FullCitation": "Nishikawa K, et al. Int. J. Cancer (2017) pmid: 27521503", "Include": "true"}, {"number": "474", "ReferenceId": "23729232", "FullCitation": "Bian L, et al. Tumour Biol. (2013) pmid: 23729232", "Include": "true"}, {"number": "475", "ReferenceId": "22257673", "FullCitation": "Baselga J, et al. Lancet (2012) pmid: 22257673", "Include": "true"}, {"number": "476", "ReferenceId": "24095300", "FullCitation": "Robidoux A, et al. Lancet Oncol. (2013) pmid: 24095300", "Include": "true"}, {"number": "477", "ReferenceId": "24457911", "FullCitation": "Alba E, et al. Br. J. Cancer (2014) pmid: 24457911", "Include": "true"}, {"number": "478", "ReferenceId": "25779558", "FullCitation": "Gelmon KA, et al. J. Clin. Oncol. (2015) pmid: 25779558", "Include": "true"}, {"number": "479", "ReferenceId": "24868024", "FullCitation": "Satoh T, et al. J. Clin. Oncol. (2014) pmid: 24868024", "Include": "true"}, {"number": "480", "ReferenceId": "25694417", "FullCitation": "Lorenzen S, et al. Eur. J. Cancer (2015) pmid: 25694417", "Include": "true"}, {"number": "481", "ReferenceId": "20857170", "FullCitation": "Galsky MD, et al. Invest New Drugs (2012) pmid: 20857170", "Include": "true"}, {"number": "482", "ReferenceId": "26628478", "FullCitation": "Hecht JR, et al. J. Clin. Oncol. (2016) pmid: 26628478", "Include": "true"}, {"number": "483", "ReferenceId": "19825948", "FullCitation": "Burris HA, et al. Clin. Cancer Res. (2009) pmid: 19825948", "Include": "true"}, {"number": "484", "ReferenceId": "17704424", "FullCitation": "Chu QS, et al. J. Clin. Oncol. (2007) pmid: 17704424", "Include": "true"}, {"number": "485", "ReferenceId": "21778300", "FullCitation": "Chew HK, et al. Ann. Oncol. (2012) pmid: 21778300", "Include": "true"}, {"number": "486", "ReferenceId": "17671135", "FullCitation": "Siegel_Lakhai WS, et al. Clin. Cancer Res. (2007) pmid: 17671135", "Include": "true"}, {"number": "487", "ReferenceId": "24800949", "FullCitation": "Tan AR, et al. Br. J. Cancer (2014) pmid: 24800949", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_09_16 00:42:45", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "796x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary adenocarcinoma", "flowcell_analysis": "2000023529", "gender": "female", "pathology_diagnosis": "Adenocarcinoma, metastatic", "percent_tumor_nuclei": "40", "pipeline_version": "v3.14.0", "purity_assessment": "50.0", "specimen": "ORD_1450681_01*US1390521.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1450681_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "949.87", "name": "SQ_US1390521.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4519", "cds_effect": "125A>G", "depth": "894", "equivocal": "false", "functional_effect": "missense", "gene": "ATM", "percent_reads": "45.19", "position": "chr11:108098555", "protein_effect": "H42R", "status": "unknown", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"allele_fraction": "0.567", "cds_effect": "979C>T", "depth": "448", "equivocal": "false", "functional_effect": "nonsense", "gene": "MAP2K4", "percent_reads": "56.7", "position": "chr17:12032543", "protein_effect": "Q327*", "status": "likely", "strand": "+", "transcript": "NM_003010", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"allele_fraction": "0.4915", "cds_effect": "961G>A", "depth": "468", "equivocal": "false", "functional_effect": "missense", "gene": "BAP1", "percent_reads": "49.15", "position": "chr3:52439281", "protein_effect": "A321T", "status": "unknown", "strand": "_", "transcript": "NM_004656", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"allele_fraction": "0.5125", "cds_effect": "731G>T", "depth": "519", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "51.25", "position": "chr17:7577550", "protein_effect": "G244V", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"allele_fraction": "0.1302", "cds_effect": "2278C>T", "depth": "653", "equivocal": "false", "functional_effect": "missense", "gene": "STAG2", "percent_reads": "13.02", "position": "chrX:123202426", "protein_effect": "R760C", "status": "unknown", "strand": "+", "transcript": "NM_006603", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"allele_fraction": "0.1845", "cds_effect": "1453delC", "depth": "656", "equivocal": "false", "functional_effect": "frameshift", "gene": "FANCC", "percent_reads": "18.45", "position": "chr9:97869427", "protein_effect": "Q485fs*2", "status": "likely", "strand": "_", "transcript": "NM_000136", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"allele_fraction": "0.483", "cds_effect": "817G>A", "depth": "824", "equivocal": "false", "functional_effect": "missense", "gene": "FH", "percent_reads": "48.3", "position": "chr1:241669390", "protein_effect": "A273T", "status": "known", "strand": "_", "transcript": "NM_000143", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"allele_fraction": "0.5274", "cds_effect": "434G>A", "depth": "749", "equivocal": "false", "functional_effect": "missense", "gene": "RNF43", "percent_reads": "52.74", "position": "chr17:56440903", "protein_effect": "R145Q", "status": "unknown", "strand": "_", "transcript": "NM_017763", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"allele_fraction": "0.8166", "cds_effect": "239T>C", "depth": "578", "equivocal": "false", "functional_effect": "missense", "gene": "FANCC", "percent_reads": "81.66", "position": "chr9:98009725", "protein_effect": "I80T", "status": "unknown", "strand": "_", "transcript": "NM_000136", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"allele_fraction": "0.2558", "cds_effect": "133T>C", "depth": "684", "equivocal": "false", "functional_effect": "missense", "gene": "CTNNB1", "percent_reads": "25.58", "position": "chr3:41266136", "protein_effect": "S45P", "status": "known", "strand": "+", "transcript": "NM_001904", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"allele_fraction": "0.151", "cds_effect": "965T>A", "depth": "596", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB4", "percent_reads": "15.1", "position": "chr2:212578292", "protein_effect": "M322K", "status": "unknown", "strand": "_", "transcript": "NM_005235", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "0", "equivocal": "false", "gene": "CDKN2B", "number_of_exons": "5 of 5", "position": "chr9:21998748_22101832", "ratio": "0.34", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "VEGFA", "number_of_exons": "8 of 8", "position": "chr6:43738443_43752419", "ratio": "1.84", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21954944_21998002", "ratio": "0.34", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"copy_number": "204", "equivocal": "false", "gene": "CDK12", "number_of_exons": "13 of 14", "position": "chr17:37627131_37687569", "ratio": "38.05", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}, {"copy_number": "150", "equivocal": "false", "gene": "ERBB2", "number_of_exons": "27 of 27", "position": "chr17:37807689_37884297", "ratio": "41.64", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}]}, "rearrangements": {"rearrangement": {"description": "LYN(NM_002350) rearrangement intron 2", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "pos1": "chr8:56858981_56859213", "pos2": "chr1:117285690_117285958", "status": "unknown", "supporting_read_pairs": "99", "targeted_gene": "LYN", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1390521.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.21", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}